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ABSTRACT
MECHANISM OF TAU PROPAGATION. PUTATIVE THERAPEUTIC APPROACHES.
by
Viktoriya Morozova

Advisor: Alejandra Del Carmen Alonso

One of the characteristics of Alzheimer’s disease and associated tauopathies is the
accumulation and aggregation of hyperphosphorylated tau protein. The biological activity
of tau is to bind to tubulin and promote its’ assembly into microtubules
with subsequent stabilization of the latter. When tau gets hyperphosphorylated it cannot
bind to tubulin and carry on its function, instead, it binds to normal tau and sequesters it
from microtubules leading to disruption of microtubular assembly and ultimately to the
death of neurons. Our lab had previously shown that tau phosphorylation sites 199, 212,
231, and 262, combined with the FTDP-17 mutation R406W (Pathological Human tau or
PH-Tau) are critical for inducing a conformational change in the protein similar to the
abnormally hyperphosphorylated tau from AD brain. Moreover, it was proposed that
hyperphosphorylated tau can transfer between the cells in a prion fashion leading to more
microtubular disruption. This research was designed to investigate the role of
phosphorylated tau in the mechanism of tau transfer from one cell to another in vitro and
in vivo and its effect on memory. I found that tau can be taken up by the cells and neurons
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when added to the cell media and this uptake is mediated by the M1 and M3 muscarinic
receptors. M1 muscarinic receptor inhibitor Pirenzipine similarly to Atropine, a broad
muscarinic receptor antagonist is able to block almost 80 percent of tau uptake, while
PTX and AF-DX116, M2 antagonist, and M2 and M4 downstream blockers respectively,
had no impact on tau PH-PH-Tau uptake, Moreover, once again I confirmed that effect of
PH-Tau on primary neuronal cultures is very similar to tau isolated from the brain of the
patient with Alzheimer disease and leads to almost complete disruption of neurites and
microglial activation. On the other hand, the incubation of primary cultures with tau
resulted in enhanced growth of neurites. I also found that all the tau isoforms can be taken
up by the neurons and preincubation with atropine significantly reduces their uptake.
However, the highest uptake I observed was with the largest tau isoforms, and this uptake
was significantly reduced with the isoforms with an absent 2N domain. The intracranial
hippocampal injections of PH-Tau lead to cognitive decline in CD1 mice within 6 months
after the injection. Furthermore, Direct Current (DC) stimulation is the technique that was
shown to upregulate chaperone proteins. These proteins are involved in targeting
misfolded proteins and aggregates. Here I investigated the effect of DC stimulation on
human cells and primary neuronal cultures that were exposed to pathological tau and the
brain of our transgenic mice expressing high amounts of hyperphosphorylated tau. I found
that DC stimulation resulted in an increase in HSP70 proteins in vitro and in vivo. I also
found the reduction in PH-Tau in vitro and in vivo most likely due to the upregulation of
the degradation pathway.
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BACKGROUND
Tauopathies and tau
Tauopathies are the family of neurodegenerative diseases, such as Alzheimer’s Disease
(AD), Parkinson’s Disease, Frontotemporal Dementia with Parkinsonism linked to
chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Amyotrophic Lateral
Sclerosis (ALS), Traumatic Brain Injury (TBI) and others (Hutton et al., 1998; Poorkaj et
al., 1998). These diseases are heterogeneous in their clinical, morphological, and
biochemical characteristics and united by a similar mechanism where the accumulation
of abnormal tau protein in cytosol results in the formation of paired helical filaments and
straight filaments inside the neuron (Alonso et al., 1986). The pathological tau also, can
bind to normal tau protein and sequester it from the microtubules resulting in disruption
of microtubules, and ultimately in the death of neurons (Alonso et al., 1996, 2006, 2010)
Tau is a neuronal microtubule-associated protein (MAP), and its best characterized
biological function is to promote the assembly of tubulin into microtubules and subsequent
stabilization of those assembled microtubules (Drubin and Kirschner, 1986 Grundke-Iqbal
et al., 1986) This protein is encoded by the MAPT gene, located on chromosome 17
(Andreadis 2006; Wang et. al.,2016). Six isoforms of tau protein ranging from 37–46 kDa
(352-441 amino acids) were
identified in the human central nervous system (CNS) (Goedert et al., 1989, 1992a). these
isoforms are the result of alternative splicing of exons 2, 3, and 10 and result in the protein
with absent or present 1 or 2 N-terminal domains (0N, 1N, 2N) and 3 or 4 C-terminal
microtubule-binding repeats (3R, 4R) (Goeder,1989). Tau protein could be divided into
four major regents or domains. These domains differ in their biochemical properties. The
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N-terminal is an acidic projection domain comprised of amino acids 1–150 and contains
two alternatively spliced N-terminal inserts. The proline-rich domain is the region of tau
that encompasses residues 151–243 and it is comprised of seven Proline (Pro) rich motifs
(ProXXPro). This domain is recognized by many tau binding partners including actin and
interactions with DNA and RNA. This domain also plays a vital role in the regulation of
microtubular assembly. The microtubule-binding domain consists of four imperfect
repeats which are separated by flanking regions. Together these microtubule-binding
domains provide the primary structures by which tau binds to tubulin and stabilizes
microtubules. Finally, amino acids 370–441 form the C-terminal tail of tau (Hanger et., al,
2017).

Tau protein was discovered in 1975 (Weingarten, 1975) during his experiments on tubulin
assembly into the microtubules. In his study, he identified the protein necessary for 6s
tubulin to form 36s tubulin and then the assembly of the latter into the microtubules. In
the very same study, he proposed to call that protein tau. Two years later it was noted
that tau is a phosphoprotein. In the human brain, the longest isoform of tau contains 80
Serine (Ser) and Threonine (Thr) and five Tyrosine (Tyr) residues which
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means that almost 20% of the protein can be phosphorylated (Shahani, 2002). Besides
phosphorylation, nearly 35 percent of the amino acid residues that might undergo peri or

Fig1. Tau protein scheme: Tau protein is the product of the alternative splicing of the
MAPT gene located on chromosome 17q21. MAPT gene consists of 16 exons, however
first and the last exons are transcribed but not translated’ Six tau isoforms are found in
the human central nervous system ranging from 352 to 441 amino acids. The isoforms
differ from each other by the amounts of N terminals (0N, 1N(yellow), and 2N(green))
and the amounts of microtubule-binding domains 3 repeats or 4repeats (3R, 4R, white),
where the second microtubule-binding repeat (R2, white sage) is present or absent. All
six isoforms can be found in the adult human brain in approximately equal amounts. the
fetal human brain expresses only the shortest tau isoform (352aa; 0N3R)

post-translational modification in tau are susceptible to modification on the longest
isoform of the tau molecule. (Darling and Uversky, 2018; Barber and Rinehart, 2018).
These residues are serine (Ser), threonine (Thr), tyrosine (Tyr), lysine (Lys), arginine
(Arg), asparagine (Asp), histidine (His), and cysteine (Cys). The modifications that were
found on tau are: phosphorylation on Ser, Thr, or Tyr; acetylation, ubiquitination,
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SUMOylation, and glycation on Lys; methylation on Lys or Arg; O-GlcNAcylation on Ser
and Thr, N-glycosylation on nitrogen (reviewed by Alquezar et al., 2021)
Acetylation
Acetylation is the protein modification where the acetyl group is added to the lysine
residue of the protein. The longest tau isoform has 44 lysine residues, which could be
potentially acetylated (Kamah et al., 2014). Besides the neutralization of lysine, this
modification regulates a variety of cellular processes such as protein folding, signal
transduction, metabolism, and autophagy. The acetylation of tau and its role in health and
disease is not fully understood. This modification, depending on lysine residue will have
a different effect on tau. For example, the acetylation of tau at Lys 280 leads to the
weakening of the tau binding to microtubules and can result in the destabilization of the
microtubules (Cohen et al., 2011; Irwin et al., 2012). The acetylation at Lys 174 does not
affect tau binding to microtubules but results in tau aggregation (Min et al., 2015). In
contrast, tau acetylation at KXGS microtubule binding motif (Lys 259, Lys 290, Lys 321,
or Lys 353) leads to suppression of tau phosphorylation and aggregation (Cook et al.,
2015). Besides that, this modification can also impact other protein properties by
competing with other modifications such as ubiquitination, SUMOylation, and glycation
on lysine residues and therefore block the processes that are regulated by those
modifications (Morris et al., 2015)
Ubiquitination
The ubiquitination of the target protein occurs at lysine residues. Even though the longest
tau isoform has 44 lysine residues, only 17 were found to be ubiquitinated (Morris et al.,
4|Page
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2015). Most of those sites are located on the MTBD of the protein (Morris et al., 2015;
Munari et al., 2020). The ubiquitin molecule itself consists of 7 lysine residues and the
number of the lysine residue that is linked to the target protein will determine the biological
effect of the ubiquitination. The ubiquitinated tau is mainly found in the diseased brain
and is the component of the NFT (Morishima-Kawashima et al.; 1993; Riederer et al.,
2009). However, in pre-tangled tau, no ubiquitination is found (Bancher et al., 1991;
García-Sierra et al., 2012) The ubiquitination of tau protein is linked mainly to protein
degradation through the 26S proteasome or its shift to the autophagy-lysosomal pathway.
Post-translational tau modifications that occur at lysine residues can potentially block the
ubiquitination of tau, therefore, resulting in a decrease in tau degradation. The
ubiquitination also can be blocked by modifications that do not target lysines, such as
phosphorylation of tau at the C-terminal at the KXGS microtubule-binding motif (Dickey
et al., 2007)
SUMOlyation
SUMOlyation is the modification where a small ubiquitin-like protein is added to the lysine
residue of the target protein (Sarge and Park-Sarge, 2009). The SUMOlyation plays a
crucial role in different nuclear processes such as gene expression, DNA damage
response, stability of the genome (Muller et al., 2004; Jackson and Durocher 2013), and
protein trafficking (Melchior et al., 2003). Tau was found to be available to SUMOlyation
only when it’s unbound from microtubules and this modification occurs at lysine 340
therefore it blocks the ubiquitination and consequent degradation through the 26S
proteasomal pathway. This might result in tau accumulation and aggregation.
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Methylation
Methylation is the post-translational modification of the protein where the methyl group is
added to the lysine residue of the target protein. The lysine on the target protein can be
methylated up to 3 times resulting in mono, di, or trimethyl-lysine. (Alquezar et al., 2021).
This modification results in increased hydrophobicity of the target protein and increased
bulkiness of the lysine (Lanouette et al., 2014) Methylation plays an important role in
regulating various protein functions, such as protein-protein and protein-nucleic acid
interactions, stability of the protein, and its subcellular localization (Lanouette et al., 2014;
Kontaxi et al., 2017; Huseby et al., 2019). In the human brain, tau was found to be mono
or di methylated in both, health and disease. It was also noted that the amount of
methylation increases with age therefore it is not clear if this modification can be
associated with the disease itself, especially since the role of tau protein remains elusive
(Thomas et al, 2012). Interestingly, in mice brains this modification was also found in
arginine residues of tau, however, no such findings were recorded in the human brain
(Morris et al., 2015). In competition with other tau post-translational modifications,
methylation can compete with ubiquitination and therefore block tau’s degradation
through the ubiquitin proteasomal pathway, potentially contributing to tau accumulation
and aggregation (Thomas et al., 2012).
Glycosylation
This is a process that involves the addition of carbohydrate chains to the protein. The
glycosylation occurs with the help of the glycosyltransferase enzymes which attach
activated monosaccharides to proteins through covalent, glycosidic linkages (Liu, et al.,
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2010; Aebi, 2013; Sharma and Vijayan, 2011). During glycosylation, sugar groups are
attached to asparagine (N-glycosylation) or to serine and threonine (O-glycosylation)
residues (Reily, et al., 2019). This modification plays a major role in protein stability,
folding, solubility and oligomerization. Tau was found to undergo N-glycosylation,
exclusively during pathological conditions (Wang et.al., 1996; Sato et al., 2001). Tau
protein can additionally undergo O-GlcNAcylation. This is the type of glycosylation that
differs from other types of glycosylation in that the glycan does not process further after
the addition of a single GlcNAc to Ser or Thr residues. Because this process involves Ser
and Thr residues which also can be phosphorylated and both modifications might
compete, or these modifications can regulate each other (Yang and Qian, 2017). OGlcNAcylated tau is found mostly in the normal, control brain and it was proposed that
this modification has protective properties (Liu et al., 2004; Cheng et al., 2000)

Besides phosphorylation tau can undergo a wide range of posttranslational modifications
such as acetylation, glycation, isomerization, nitration, SUMOylation, and ubiquitination
(Morris et al., 2011) and alteration in these modifications can affect tau physiological
activity and potentially result on pathological conditions. Although tau can undergo all
these modifications, phosphorylation is the most studied modification, and in this
document, I will talk about tau as a phosphoprotein. Tau contains ~3 moles of phosphate
per mole of protein; however, its hyperphosphorylated form may contain
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7-10 moles of phosphate per mole of protein which results in the appearance of new
phosphorylated sites (Kopke et al, 1993). When hyperphosphorylated, tau forms paired
helical filaments (PHFs) which form the neurofibrillary tangles (NFTs) found in Alzheimer's
disease brain (Trojanowski and Lee, 1994; Alonso et al., 2001; Sato et al., 2002; Perez
et al., 2003). Unlike normal tau, soluble hyperphosphorylated tau taken from AD patients
(AD P-tau) does not promote microtubule assembly and can promote toxicity as shown

Fig2. PH-Tau scheme: N1 and N2 represent the two amino-terminal inserts of 29 amino acids
each, and R1, R2, R3, and R4 represent four microtubule-binding repeats of 31 or 32 amino
acids each. S199 (Serine 199), Thr212 (Threonine 212), Thr231 (Threonine 231), and S262
(Serine 262) are the pseudophosphorylation sites indicated in black. The
pseudophosphorylation is achieved by the substitution of Serine/Threonine for Glutamic acid
(E). FTDP-17 mutation R406W is indicated in red.

previously in vitro, in cells, and in vivo, in animal models (Alonso et al., 1994, Brandt et
al., 2005; Yoshiyama et al., 2007; Gomez de Barreda et al., 2010). Instead, abnormal AD
P-tau binds normal tau, sequestering it from interactions with tubulin and producing
bundles of filaments visible by electron microscopy (Alonso et al, 1996). It was shown
previously, that pseudophosphorylation of tau at Ser199, Thr212, Thr231, and Ser262
with the inclusion of the FTDP-17 R406W (Fig.2) mutation results in a protein that mimics
the effect of AD P-tau in cell culture (Alonso et al, 2010; Morozova et. al.,2019). The
pseudophosphorylation of tau molecule on sites named above was done by substitution
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of Ser and Thr sites on Glu (glutamic acid). This protein, named Pathological Human Tau
(PH-Tau), has been studied in mammalian cell culture, Drosophila, and mouse models
(Alonso et al., 2010; Beharry et al., 2013; Di et al., 2016). The expression of PH-Tau
induced microtubule disruption in all systems and resulted in cognitive and behavioral
impairment in Drosophila and mice. (Alonso 2010; Beharry et al., 2013; Di et al., 2016).
Upon hyperphosphorylation, tau can bind to normal tau and displace it and other MAPs
from the microtubules inducing instability. The development of the tauopathies, such as
AD occurs in well-defined stages described by Braak in 1991. Six stages of
neuropathology based on the distribution of neurofibrillary tangles were identified. At
stage I, neurofibrillary tangles are present primarily in neurons in the transentorhinal
cortex. At the stage II neurofibrillary tangles can be found in both transentorhinal and
entorhinal cortexes. During stage III, the transentorhinal and entorhinal cortexes are
affected more severely and pathology spreads further into the hippocampus. Stage IV is
characterized by the presence of neurofibrillary tangles in cortical layers and in subcortical
nuclei. And finally, during stages V and VI neurofibrillary tangles spread into the
association cortex areas (Braak et al.,1991; 2011). The fact that there is an orderly
progression suggests that the seeding mechanism of tau is a prion-like property that may
explain further disease propagation in the brain with the release of tau from one neuron
and uptake by another.
Recently tau was found in the extracellular space, however, what is the role of intracellular
tau released to the extracellular space is not well understood. (Karch et. al., 2012; Michel
et. al., 2014; Chai X, Dage et al.,2012; Pooler et. al., 2013; Gendreau et. al., 2013). When
in extracellular space, tau could possibly interact with surrounding neurons and, result in
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an increase in intracellular calcium in those neurons (Gomez-Ramos, et al., 2006). This
increase in calcium could be because of the activation of calcium-permeable channels,
or due to the stimulation of cell surface receptors coupled to calcium influx. Another
reason for intracellular calcium raise is calcium freeing from intracellular stores, such as
the Endoplasmic Reticulum, initiated by the activation of metabotropic receptors for
example muscarinic receptors (Gomez-Ramos et al., 2006).
Muscarinic acetylcholine receptors
Muscarinic acetylcholine receptors (mAChRs) are the class of metabotropic receptors,
and they are members of a G-protein coupled receptor family (Krnjevic, 1974; Buckley et.
al.,1992; Caulfield, 1993). These receptors mediate most of the inhibitory and excitatory
effects of acetylcholine (Ach) in the central and peripheral nervous system which in turn
modulate a variety of physiological functions and could be a potential target in diseases
such as Alzheimer’s, Parkinson’s, and Schizophrenia. There are five subtypes of
muscarinic receptors M1-M5, which could be divided into two categories: excitatory M1,
M3, and M5, and inhibitory M2 and M4. The activation of the excitatory receptor group
(Gq) activates the phospholipase C pathway leading to the release of inositol
triphosphate, which results in the mobilization of intracellular calcium (Felder, 1995).
Conversely, activation of the inhibitory receptor group results in an inhibition of PKA and
leads to a decrease in the intracellular levels of cAMP (Felder, 1995).
Research data indicated that the muscarinic receptors are the ones involved in the
interaction with extracellular tau, and this interaction results in raising intracellular calcium
(Gomez-Ramos et al., 2008, Avila et al., 2014., Wysocka et al., 2020). Data had shown
that muscarinic receptors, specifically M3 have a higher affinity to tau than to
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Acetylcholine (Gomez-Ramos et al., 2009), meaning that the presence of extracellular
tau and its interaction with muscarinic receptors may result in the continuous release of
calcium and therefore on increasing calcium levels inside the cells leading to cell death.
The death of the cell (neuron) may result in the release of the intercellular tau which in
turn may interact with muscarinic receptors and further propagate neurodegeneration and
cell death (Gomez-Ramos et al., 2009) The transmission of pathological tau between the
neurons may occur not only upon the death of neuron and release of tau into extracellular
space. Tau could also be transferred from cell to cell via exocytosis and endocytosis
(Clavaguera et al., 2009; Frost et al., 2009; de Calignon et al., 2012; Liu et al., 2012; Wu
et al., 2012; Iba et al., 2013). It’s not well understood if endocytosis can occur in all types
of cells, or if this process requires cells to express a particular receptor or receptors. In
this document, I will show that indeed, the tau transfer does not occur in all cell types and
the presence of muscarinic receptors, M1 and M3 is required.
My preliminary data indicated that pretreatment of neuronal cultures with broad
muscarinic receptor antagonist atropine prior to tau/PH-Tau addition reduces protein
uptake, pointing out that muscarinic receptors are involved in PH-Tau ability to enter the
cells leading to accumulation and aggregation in the perinuclear region, with subsequent
disruption of the recipient cell. In my work, I further investigated the involvement of these
receptors in tau and PH-tau propagation in vitro. Here I will show that indeed, excitatory
muscarinic receptors play a vital role in the ability of tau to enter the cells, and blocking
of these receptors can prevent/reduce PH-Tau uptake and the disruption of the
microtubular networks.
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Direct current stimulation
Transcranial Direct Current Stimulation (tDCS) is a popular technique in treating mood
disorders and depression due to the modulation of cortical activity (Nitsche et al., 2000).
Also, it has been shown that tDCS improves memory and learning in healthy individuals
(Sandrini et al., 2012) and it was proposed that this technique could be used in patients
with neurodegenerative disorders, such as Alzheimer's disease to improve memory
(Pellicciari et al., 2018) however, the data does not support the notion that tDCS
stimulation shows clear therapeutic efficacy in patients with mild cognitive impairment.
On the other hand, the data indicate that DCS promotes the upregulation of heat shock
proteins (Mekhael et al., 2019), which are responsible for the identification and
degradation of misfolded proteins.
Here I investigated the effect of DC stimulation on heat shock protein expression and PHTau accumulation

in vitro, using healthy neurons and neurons undergoing

neurodegeneration due to exposure to PH-Tau. I also investigated the effect of tcDCS in
vivo using a murine model. I hypothesized, that an increase in heat shock proteins due to
DCS stimulation would result in the enhancement of misfolded protein degradation which
may slow down neurodegeneration in neurons exposed to PH-Tau.
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CHAPTER 1

Normal and Pathological Tau Uptake Mediated by M1/M3 Muscarinic Receptors
Promotes Opposite Neuronal Changes

Abstract
The microtubule-associated protein tau is mainly found in the cell’s cytosol but recently it
was also shown in the extracellular space. In neurodegenerative diseases, like
Alzheimer’s disease (AD), pathological tau spreads from neuron to neuron enhancing
neurodegeneration. Here, we show that HEK293 cells and neurons in culture uptake
extracellular normal and pathological tau. Muscarinic receptor antagonist atropine and
pirenzepine block 80% of this uptake. CHO cells do not express these receptors and
therefore cannot uptake tau unless transfected with M1 and/or M3 receptors. These
results strongly suggest that muscarinic receptors mediate this process. Uptake of normal
tau in neurons enhances neuronal process formation but a pseudophosphorylated form
of tau (pathological human tau, PH-Tau) disrupts them and accumulates in the
somatodendritic compartment. AD hyperphosphorylated tau (AD P-Tau) has similar
effects as PH-Tau on cultured neurons. Addition of either PH-Tau or AD P-tau to neuronal
cultures induced microglial activation. In conclusion, uptake of extracellular tau is
mediated by muscarinic receptors with opposite effects: normal tau stabilizes neurites,
whereas pathological tau disrupts this process leading to neurodegeneration.
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Introduction

Tau is a neuronal cytosolic microtubule-associated phosphoprotein whose function can
be influenced by post-translational modifications. Abnormally phosphorylated tau is a
common denominator in several types of dementia, including Alzheimer’s disease (AD)
and other tauopathies (Goedert et al., 2010; Beharry et al., 2014).

Unlike normal tau, soluble hyperphosphorylated tau taken from AD patients (AD P-tau)
does not promote microtubule assembly. Instead, AD P-tau binds normal tau,
sequestering it from interactions with tubulin and producing bundles of filaments observed
by electron microscopy (Alonso et al., 1996). This suggests that differences in tau
phosphorylation states could affect its conformation and subsequently alter proteinprotein interactions and tau biological function. Seeding activity into self-assembled
aggregates can lead to the development of neurofibrillary tangles. Our lab has shown
previously that pseudophosphorylation at Ser199, Thr212, Thr231, and Ser262 with the
inclusion of the FTDP-17 R406W mutation (Pathological Human Tau, PH-Tau) results in
a protein that mimics the effect of AD P-tau in culture (Alonso et al., 2010). This protein
has been studied in mammalian cell culture, Drosophila, and mouse models. The
expression of PH-Tau induced microtubule disruption in all systems and resulted in
cognitive and behavioral impairment in Drosophila and mice (Alonso et al., 2010; Beharry
et al., 2013; Di et al., 2016).

In AD, the initial neurodegenerative lesions are in the transentorhinal cortex spreading
slowly to the hippocampus and neocortex (Hyman et al., 1984; Braak and Braak, 1991;
Goedert et al., 2010), leading to cognitive decline. It was proposed that pathological tau
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is spread from cell to cell in a prion-like fashion (Holmes and Diamond, 2014; Mudher et
al.,

2017).

The

seeding

and

propagation

of

filamentous

structures

by

hyperphosphorylated tau has been a central point in AD research (Alonso et al., 2016;
Hu et al., 2016; Iqbal et al., 2016; Mudher et al., 2017; Shafiei et al., 2017). Cells in culture
take up tau aggregates ranging in size from oligomers and short filaments (neuronal cells)
to fibrils (non-neuronal cells) through endocytosis (Frost et al., 2009; Nonaka et al., 2010;
Guo and Lee, 2011; Wu et al., 2013; Sanders et al., 2014; Wu et al., 2016). Recently, it
has been shown that monomeric tau can enter neurons (Evans et al., 2018), and based
on the kinetics of tau uptake, it was suggested that this might be a receptor-mediated
process (Evans et al., 2018). Furthermore, intracerebral injections of abnormal tau
showed that tau pathology propagates away from the injection site to neighboring brain
regions indicating that tau can be transferred from cell to cell (Bolmont et al., 2007;
Clavaguera et al., 2009; Lasagna-Reeves et al., 2012; Clavaguera et al., 2013; Iba et al.,
2013; Wu et al., 2013; Ahmed et al., 2014; Clavaguera et al., 2014). Taken together,
these results have led to the tau propagation hypothesis in which tau is released from
one neuron into the intra-neuronal space and taken up by other neurons transferring tau
toxicity in a similar fashion as prion proteins (as reviewed in Takeda, 2019).

In this study, I demonstrated that the addition of recombinant tau protein to the culture
media of Human Embryonic Kidney cells (HEK293) and primary cerebellar neuronal
culture results in the uptake of tau and PH-Tau. Chinese Hamster Ovary (CHO) cells are
unable to uptake tau unless they are transfected with M1- and M3-type muscarinic
receptors. Furthermore, uptake into both HEK293 cells and cerebellar neurons is blocked
by atropine, a muscarinic receptor antagonist, and uptake in cerebellar neurons is blocked
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by pirenzepine, an M1 antagonist, but not AF-DX116, an M2 antagonist, or pertussis toxin
(PTX), an M2/M4 antagonist. Neuronal cultures incubated with wild-type tau for 7 days
show an abundant and well-organized neuritic arbor. Similar cultures exposed to PH-Tau
and AD P-tau show accumulation of tau in the somatodendritic neuronal compartment
and disruption of neuronal processes. My experimental results suggest that both tau and
pathogenic tau are taken up in mammalian cells and neurons in a muscarinic receptormediated uptake mechanism that facilitates long-term neuronal changes.

Materials and Methods

Antibodies

The primary antibodies used in this work are as follows: tau-13 (mouse, 1:1,000,000 for
Western blot, 1:1000 for immunohistochemistry), CHRM1 (rabbit, 1:1000, Invitrogen,
Cat#711098), βactin (1:2500, Santa Cruz, Cat#SC4778), β-III tubulin (chicken, 1:1000,
Abcam, Cat#AB107216), GFAP (rabbit, 1:1000, Invitrogen Cat#PA3-16-727), IbaI (rabbit,
1:1000, Wako Cat#019-19741). The secondary antibodies used in this work are as
follows: anti-mouse IgG-HRP (1:2000, Santa Cruz, Cat#SC-516102), anti-mouse Alexa
488 (1:1000, Invitrogen, Cat#A21202), anti-chicken Alexa 555 (1:1000, Invitrogen,
Cat#A21437), anti-rabbit Alexa 594 (1:1000, Invitrogen, Cat#A21203). Tau-13 antibodies
were a gift from Dr. Nicholas Kanaan at Michigan State University (originally created by
Dr. Lester Binder at Northwestern University).

16 | P a g e

Viktoriya Morozova

Doctoral Dissertation

Recombinant Protein Expression and Purification
GST-tagged proteins were transformed into BL21(DE3) pLysS cells. The overnight
cultures were resuspended with fresh LB and grown till OD 600 reaches 0.8 after which
the cultures were induced for 2,5 hours with 0.8mM IPTG.

Induced cultures were

centrifuged, and pellets were stored at -80 degrees centigrade until the next day. Pellets
were resuspended using NETN buffer (20mM Tris, 1mM EDTA,100mM NaCl, and 0.5%
Nonidet) containing proteases and phosphatases and then lysosome was added to a total
concentration of 0.5mg/ml and cultures were incubated on ice with agitation for 40min,
sonicated 5 times 20 seconds on and 20 seconds off, centrifuged at 3000 x g for 30 min
and the supernatant was transferred in the column containing glutathione-sepharose
beads (GE Healthcare). The crude extract was incubated with the beads overnight at 4
degrees with agitation, then beads were washed with fresh NETN buffer prior to elution
and eluted in elution buffer (100mM Tris, 120mM NaCl, 20mM Reduced Glutathione).
Eluted protein was dialyzed in MES buffer with 20 percent glycerol and stored at -80
degrees Celsius until needed.
Protein Quantitation, PAGE, and Western Blot Analysis

Quantitation of protein samples was performed by either the Bradford assay or by UV
quantitation. The Bradford assay was performed on recombinant proteins and cell and
neuronal lysates as described by the BioRad manual. The recombinant protein was also
determined by UV spectroscopy at 280 nm using the extinction coefficients of 50685 M−1
cm−1 for GST-tau, 56185 M−1 cm−1 for GST-PH-Tau, and 43110 M−1 cm−1 for GST.
Recombinant proteins (10 µg per lane), and cell and neuronal lysates (7 µg per lane) were
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analyzed by SDS-PAGE and Western blot as described with some modifications
(Grundke-Iqbal et al., 1984).

Cell Culture and Transfection

HEK293 cells were grown in DMEM cell media supplemented with 10% Fetal Bovine
Serum (FBS), sodium pyruvate, Glutamax, and Antibiotic-Antimitotic. CHO cells were
grown

in

FK12

media

with

10%

FBS,

sodium

pyruvate,

Glutamax

and

AntibioticAntimitotic. Media components were from Gibco or Thermo Fisher Scientific.
Chinese Hamster Ovary cells were plated on glass coverslips overnight. Transfections
were performed using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA, United States),
according to the manufacturer’s instructions. Briefly, transfections were performed in
serum-free media OptiMEM using 3 µg of total DNA and 3 µl of LipofectamineTM 2000
per 35 mm dish. Cells were incubated in transfection media for 4 h and then replaced with
fresh cell media.

Preparation of Mixed Cerebellar Neuronal Culture

Cerebellar granule cells were prepared from PN7 CD1 mice. The cerebellum was
removed, and the single cell suspension was prepared by trypsinization and trituration in
1% trypsin in Ca2+, Mg2+ free isotonic phosphate buffer (CMF-PBS). Cells were washed
in CMF-PBS and resuspended in a minimum essential culture medium supplemented
with 0.25% glucose, 2 mM GlutaMax, 10% Horse Serum, 5% FBS, and 25 U/ml of both
penicillin and streptomycin. Cells were seeded into PDL-coated dishes and incubated at
37◦C, 5% CO2. Twenty-four hours after neuronal isolation, culture media was changed to

18 | P a g e

Viktoriya Morozova

Doctoral Dissertation

media containing 15% of N2 supplement (R&S system) and 10 µM KCl. This media was
changed every 2 days. Media components were from Gibco, Sigma, or Corning.

Protein Addition to Cultures

GST, GST-tau, and GST-PH-Tau (0.4 µg/ml final concentration) were added to the cell
media of HEK293 cells, CHO cells, and primary neuronal cultures. HEK293 and CHO
cells were incubated with proteins for 2–4 h and washed with PBS. After additional
incubation for 48 h, cells were fixed, processed for immunocytochemistry, and viewed by
confocal microscopy. M1/M3 transfected CHO cells were incubated for 48 h, then tau or
PH-tau was added to the cells as described, incubated for 4 h, then media was changed,
and cells were grown for another 24 h and then processed for western blot. Neuronal
cultures were incubated for 24 h in the presence of tau or PH-Tau and were either fixed
and processed for immunochemistry (DIV8) or incubated for longer time periods. For
longer incubation times, half of the media was removed after 24 h and replaced with fresh
media. The cultures were fixed and processed at DIV10, DIV12, or DIV14. Blocking of
Muscarinic Receptors HEK293 cells and neuronal cultures were treated with 100 µM
Atropine sulfate salt monohydrate (Sigma), 10 µM Pirenzepine Dichloride (Alfa Aesar),
40 ng/ml Pertussis toxin (Enzo), or 10 µM AF-DX116 (Toriks Biochemicals) in the culture
media for 10 min prior to protein addition. After pre-treatment, half of the media was
removed, replaced with fresh media, and tau, PH-Tau or AD P-tau were added
immediately to the cultures and incubated as described above.
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Immunocytochemistry of Cell and Neuronal Cultures
HEK293 and CHO cells were fixed with cold methanol at −20◦C for 5 min. Fixed cells
were washed with PBS three times for 5 min and then blocked with 5% donkey serum in
PBS for 1 h at room temperature. Tau-13 was added to the blocking buffer and cells were
incubated overnight at 4◦C with agitation. Cells were washed three times for 5 min each
and incubated with anti-mouse Alexa 488 in blocking buffer (1:1000 dilution) for 2 h.
Finally, cells were washed three times with PBS and the coverslips were mounted on the
slides using Vectashield mounting media containing DAPI (Vector Laboratories, Inc.) and
viewed by confocal microscopy. Neuronal cultures were fixed with warm 4%
paraformaldehyde for 10 min at room temperature, washed with PBS three times for 5
min, and permeabilized with 100% methanol at −20◦C for 10 min. Permeabilized cells
were washed again with PBS three times for 5 min and blocked with 5% BSA, 1% Donkey
serum, and 0.2% TritonX100 in PBS for 1 h at room temperature. Tau-13, β-III tubulin,
GFAP, or IbaI were added to the blocking buffer, and cultures were incubated overnight
at 4◦C. Cultures were washed with 0.2% TritonX-100 in PBS (PBS-T) three times 5 min
each and incubated with anti-mouse Alexa 488, anti-chicken Alexa 555, or anti-rabbit
Alexa 594 in blocking buffer for 2 h at room temperature. Cultures were washed with PBST and then with PBS. Coverslips were mounted as described above. LIVE/DEAD Imaging
Neuronal cultures (DIV 14) cultured in 24-well plates were treated with reagents from the
LIVE/DEAD Cell Imaging Kit (488/570) (Invitrogen) as described by the manufacturer’s
protocol. Analysis was performed using a Zeiss-Axio Observer Z1 Live Imager.
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Stereotaxic Injections

Five-month-old CD-1 mice were anesthetized with 100 mg/kg ketamine and mounted onto
a stereotaxic apparatus and kept anesthetized under isofluorane throughout the
procedure. A midsagittal incision was made, and a hole was drilled using a Circuit Medic
Micro Drill System into the cranium according to the following coordinates set from
bregma: AP: + 2.18 mm, ML: + 2.85 mm, DV: −2.5 mm. The mice were injected with 2 µL
of 2 µg/mL of either aCSF, tau, or PH-Tau with the use of a Hamilton syringe at a rate of
0.5 µL/min for 4 min of total injection time with a KD Scientific Syringe Infusion Pump.
The incision was treated with Garamycin and closed with surgical staples, and the mice
were placed onto a heating pad while they recovered from the procedure. The mice were
sacrificed after 45 days.

Cryosectioning and H&E Staining

Mice were anesthetized with 0.3 mL urethane (1 g/mL) and transcardially perfused with
0.1 M phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA) in 0.1 M PBS
then stored in PFA followed by 30% sucrose at 4◦C. Brains were cryosectioned in sagittal
vibratome sections (50 µm) and mounted onto microscope slides. Tissue sections were
then incubated in the following order: PBS for 5 min, dH2O for 1 min, hematoxylin for 4
min, running tap water for 3–5 min, dH2O for 1 min, eosin for 2 min, 70% alcohol for 2
min, 95% alcohol for 2 min, 100% alcohol for 2 min, and xylene for 2 min. The tissue
sections were covered in a Permount/xylene solution and coverslipped. The staining was
observed with an EVOS PLc light microscope at 20×.

21 | P a g e

Viktoriya Morozova

Doctoral Dissertation

Confocal Image Acquisition, Measurements, and Statistical Analysis

Images for each set of analyses were observed under a LEICA TGS SP5 confocal laser
scanning microscope (Leica Microsystems CMSGmbH, Mannheim, Germany) and
obtained using the same gain, laser intensity, and pinhole size. Confocal images were
analyzed using ImageJ software. Images were split into blue (DAPI), green and red
channels. The same threshold was assigned to all pictures for each channel. The mean
gray value was calculated from each channel and divided by the number of nuclei. The
results were graphed and compared using Excel 2010. All experiments were performed
at least three times and at least 10 images from each experiment were analyzed.
Statistics were performed using Microsoft Excel 2010. A Two-Sample t-Test assuming
equal variances was used to compare samples. The data were reported as mean values.
An alpha level of 0.05 was used for all statistical tests. The significance was determined
based on two-tailed P values

Results
Tau Uptake Into Cells Is Receptor-Mediated
The propagation of abnormal tau in AD and other tauopathies has been proposed to occur
through cell-to-cell transfer (as reviewed in Takeda, 2019). To see if the cells expressing
normal and pathological tau can safely co-exist in the same culture, I transfected HEK293
cells with DsRed-tau and with GFP-PH-Tau separately and after the washes and
treatment with DNAse, I co-cultured them together for 24-48hours after which cells were
fixed, mounted on slides using prolong diamond with DAPI and viewed under the confocal
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microscope. I was looking for the cells that would be positive for both, tau (red) and PHTau(green) as those cells would represent tau/PH-Tau’s ability to exit the “home” cell and
enter the neighboring cell.
I found that GFP-PH-Tau was able to get out from the GFP-PH-Tau transfected HEK293
cells and enter the cells that express the DsRed-Tau (fig.1 A). However, my further

Fig. 1 Tau can be transferred between the cells that express mAchR1 and
mAchR3 receptors. HEK293 and CHO cells were transfected with GFP-PH-Tau or with
DsRed-Tau and cultured together for 48h. The transfer of GFP-PH-Tau occurred only in
HEK293 (A) no transfer was observed in Co-Cultured CHO cells (B). When DsRed-Tau
or GFP-PH-Tau co-cultured CHO cells were co-transfected with both mAchR1 and
mAchR3 we observed GFP-PH-Tau transfer into DsRed-Tau expressing cells (C). The
ICC analysis did not show any transfer of GFP-PH-Tau CHO cells expressing only one
type of receptor, mAchR1 or mAchR3 (D, E),
experiments showed that this transfer does not occur in all cell types. When I repeated
the same experiment with the CHO cell line, I saw that there was no transfer of any tau
PH-Tau between the cells (fig.1 B).
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Fig.2. SDS-PAGE analysis of GST-tau and
GST-PH-Tau. GST-tau and GST-PH-Tau
were heterologously expressed as described
in the methods section. The proteins were
analyzed by SDS-PAGE for purity. Prior to
loading, the proteins were quantitated using
the Bradford Assay. These proteins were
used in the experiments described in this
research study.

To understand the mechanism of uptake, culture media spiked with recombinant proteins
GST-tau, or GST-PH-Tau, 400 ng/mL ( Fig. 2) was added to HEK293 or CHO cells and
incubated for 4 h. After replacing the culture media, the cells were incubated in normal
media for 2 days. Cells were washed to remove all extracellular tau, fixed and labeled
with an anti-human tau antibody, counterstained with DAPI to observe the
nuclei, and analyzed by confocal microscopy. Tau and PH-Tau were taken up into the
HEK293 cells, but again no uptake was observed in CHO cells (fig3. A).
GST alone was not detected in both cell lines (data not shown). These results indicate
that tau, independent of phosphorylation state, can be uptaken in a cell-specific manner.
To determine if similar uptake can be observed in neuronal cells, primary mixed cerebellar
neuronal cultures were prepared on Day 7 after birth (DIV1). Tau and PH-Tau, each at
400 ng/mL, were added to the media at DIV7 and incubated for 24 h. After incubation,
the cultures were washed as above, fixed, processed for immunochemistry, and double-
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labeled with anti-human tau and β-III tubulin (Figure 3B). DAPI was used as a
counterstain to observe the nuclei. Both Tau and PH-Tau were taken up by neurons and
accumulated at similar levels around the cell nucleus (Figure 3B, ROI). Uptake was
observed without changes in neuritic morphology or neuronal numbers when compared
to control. Similar experiments were performed with human tau without a GST tag and
uptake was observed indicating that the uptake was due to tau and not the GST tag
(Figure 4)
The different responses between HEK293 and CHO might be because HEK cells were
generated from human embryonic kidneys having properties similar to immature neurons
and CHO cells are an epithelial cell line derived from the ovaries of Chinese hamsters
(Shaw et al., 2002; Shafer and Williams, 2004; Lin et al., 2014). Like neurons, HEK293
cells express muscarinic receptors, while CHO cells do not. Neuronal muscarinic
receptors have been shown to interact with tau (Gomez-Ramos et al., 2008; GomezRamos et al., 2009; Avila et al., 2015). Western blot analysis of these cell lines shows
that both HEK293 cells express about eight-fold higher M1 receptors (CHRM1) while
primary cerebellar neuronal cultures express more than 20-fold higher M1 muscarinic
receptors when compared to CHO cells (Figure 3D, left). Pre-treatment of cells with the
muscarinic receptor antagonist atropine resulted in reduced uptake of both recombinant
tau proteins in HEK293 cells and neuronal cultures (Figure 1A, bottom, Figure 3B, last
column). Quantitative analysis shows that tau uptake in the neuronal cultures was
reduced up to 80% of that without atropine (Figure 3C). Taken together these results
implicate the involvement of muscarinic receptors in the uptake of tau into HEK293 cells
and neurons.
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Muscarinic Receptor Subtypes M1 and M3 Are Involved in the Uptake of Tau
Given that tau is uptaken by HEK293 cells and neurons but not CHO cells, and uptake is
blocked by atropine, we wanted to further analyze which of the five main subtypes of
muscarinic receptors were involved. Primary cerebellar cultures were treated with
pirenzepine, an M1 antagonist, AF-DX116, a selective M2 antagonist, and pertussis toxin
(PTX), which blocks downstream processes of Gi G protein-coupled receptors (including
M2/M4) (Figure 3C). Pirenzepine blocked the uptake of tau and PH-Tau about 80% which
is similar to atropine. Conversely, both AF-DX116 and PTX did not block the uptake of
either tau protein significantly. These results further implicate the M1 muscarinic receptor
but not M2/M4 in the uptake of tau into the cells.
To further examine the role of muscarinic receptor subtypes in uptake into cells, CHO
cells were transiently transfected with M1-HA, M3-HA, or both. The transfected cells were
cultured for 48 h and then media containing the recombinant proteins was added as
described above. The cells were collected after 24 h, washed, lysed and analyzed by
immunoblot using anti-human tau. In CHO cells transfected with M1 or M3 there is ∼19fold increase in tau uptake (Figure 3D, right) compared to non-transfected CHO cells.
When the cells were transfected with both M1 and M3 at the same time, the level of tau
uptake increased by 31.5-fold. CHO cells transfected with either M1 or M3 appear to
uptake tau at similar levels as HEK293 cells. When both receptors are present the uptake
increases significantly. These results imply that both M1 and M3 are involved in the
uptake of tau into cells.
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Fig. 3. Uptake of tau is cell-type specific. Recombinant tau and PH-Tau (400 ng/mL)
were added to HEK293 and CHO cells (A) and to primary neuronal cultures (B). Confocal
analysis indicated that uptake occurred in HEK293 and neuronal cultures (white arrows)
but not CHO cells and was blocked by pre-treatment with atropine. In the neuronal
images, the boxed areas were zoomed 2.5× and converted (βIII-tubulin, gray; tau, green).
(C) Quantitation of tau uptake into neuronal cultures indicates that both tau (dark bars)
and PH-Tau (light bars) are uptaken at similar levels. Pre-treatment with antagonist’s
atropine and pirenzepine block the uptake of both proteins by about 80%. Conversely,
AF-DX116 and PTX do not block uptake. (D) Left: Western blot analysis of cultured cells
and neurons to analyze the presence of the M1 muscarinic receptor. Quantitation
indicated that both HEK293 and neuronal cultures have a large amount of M1 muscarinic
receptors compared to CHO cells. Right: Western blot analysis of HEK293 cells
transfected with M1, M3, or M1/M3 muscarinic receptors to determine tau uptake. The
introduction of the muscarinic receptors resulted in the significant uptake of tau into CHO
cells. Scale bar: 20 µm. All experiments were performed three times with 10 images
analyzed per experiment. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
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Consequences of Tau Exposure in Neuronal Processes
To observe changes in neurons due to the uptake of tau or PH-Tau I performed the
experiments as described above, where the neurons were exposed to tau for 24 h and
cultures were allowed to grow and differentiate for up to seven more days in vitro (Figure
5A). I found that βIII-tubulin intensity at DIV10 appears to be higher in all cultures to which
tau was added when compared to the control cultures. After this point, the cultures treated
with PH-Tau, showed decreasing intensity of βIII-tubulin. DIV12 neurons treated with PHTau began to lose neurites, a feature indicative of neurodegeneration. Interestingly, the
few neurons in cultures treated with pathogenic tau, which are still present at DIV14,
appear more like neuronal processes treated with wild-type tau than those in the control.

Fig. 4. Uptake of tau without fusion protein. The tau protein without a fusion tag was
heterologously expressed and used uptake assay in neuronal cultures. Tau was uptaken in a
similar fashion as the fusion proteins indicating that the uptake was tau-dependent and not
due to the presence of the GST-tag
Conversely, there was an increase in βIII-tubulin intensity in cultures treated with normal
tau. DIV14 neurons treated with tau appear to bundle together and to be straighter than
neurons in the control samples. Levels of βIII-tubulin in culture were quantitated at DIV14
based on the confocal acquired fluorescence (Figure 5A, graph). The quantitative
analysis confirms that by DIV14, βIII-tubulin levels increased upon addition of tau and
decreased when PH-Tau was added. Based on the observed changes in βIII-tubulin for
each sample, it appears that the uptake of tau reinforces neuritic growth, while the uptake
of PH-Tau triggers the loss of neurites and result in neurodegeneration similar to that
observed in AD. As seen in Figure 3, the initial uptake of tau was blocked by atropine and
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when these cultures were allowed to incubate for 7 days, the neurons appeared similar
to cultures without tau addition (Figure 5A, bottom images). Quantitative analysis of
cultures at DIV14 of the exposed to tau with and without atropine pre-treatment show a
significant decrease in βIII-tubulin intensity when atropine was present. The
neudegeneration that was induced by exposure to PH-Tau was significantly inhibited by
pre-treatment with atropine (Figure 5A, graph). These results indicate that muscarinic
receptors play a role in the uptake of tau and that blocking them can control the uptake
and therefore the overall condition of the neurons.
Addition of PH-Tau Results in Increased Cell Death in Neuronal Cultures
To determine if this neuronal loss was due to cell death, neuronal cultures were prepared
as described and were analyzed using the LIVE/DEAD Cell Imaging Invitrogen kit (Figure
5B). Live neurons stain green whereas cell death is indicated by red staining. There is a
significant increase in the number of red cells in the neuronal cultures treated with PHTau when compared to the tau-treated and control cultures. Additionally, the cells (red or
green) look mostly rounded, due to a loss of neuritic projections which is consistent with
the results seen above when analyzing βIII-tubulin in treated cells. The percentage of
dead cells in the neuronal cultures treated with wild-type tau is decreased 50% compared
to control mixed primary neuronal cultures. This may be correlated to the increase in βIIItubulin observed above. These results indicate that the addition of wild-type tau may play
a role in strengthening the health of the neurons. Conversely, the addition of PH-tau
results in loss of neuritic projections and induction of cellular death which is like
phenotypes seen in neurons of AD patients.
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Fig 5. Uptake of tau affects the neuritic morphology of neurons in culture. (A)
Proteins were added to the neuronal culture media as described. Over a period of 7 days,
the neurons were fixed and studied by confocal microscopy. The addition of WT tau
appears to stabilize and organize the neuronal processes whereas PH-Tau triggers a loss
if neurites over time. Pre-treatment with atropine appears to block the uptake of tau and
reduces changes in neuritic morphology. Graph: Quantitation of β-III tubulin indicates that
tau (dark bars) increases protein levels whereas PH-Tau (light bars) decreases the levels
indicating a loss of neuritic morphology. (B) LIVE/DEAD Imaging of neuronal cultures after
treatment with tau or PH-Tau. The number of dead cells increases significantly in cultures
treated with PH-Tau. Scale bar: 20 µm. All experiments were performed three times with
10 images analyzed per experiment. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001)
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Microglial Activation Is Triggered by the Presence of PH-Tau
An important component of inflammation seen in brains of patients with AD other
tauopathies is microglia activation. Therefore, I investigated if in my experiments there
was a microglial modification. The neuronal cultures analyzed contain a mixture of cells
including

neurons,

microglia,

and

astrocytes

(TABLE

1).

Primary cerebellar neuronal cultures were treated as described above and then washed
and fixed at DIV14. Immunohistochemistry was performed with antibodies against GFAP,
an astrocyte marker, and Iba1, a marker for activated microglia. It is important to note that
other subpopulations of microglia may stain for Iba-1 (Ito et al., 1998), however, I was
looking at relative changes upon addition of tau. No significant changes were found in the
levels of astrocytes as judged by the levels of GFAP in the cultured neurons (Figure 6A,
top). However, there was a significant increase in the activation of microglia in the cultures
treated with PH-Tau when compared to control and tau-treated cultures (Figure
3A bottom, and Figure 3B left graph). Further analysis of these cultures indicated that tau
uptake into the microglia was dependent on the conformation of tau as PH-Tau was taken
up to a much higher extent than the wild-type form (Figure 6B, right graph). The increase
in microglial activation was directly correlated to the amount of tau uptake in the Iba1
active cells (Figure 6B, compare left and right graphs). In cultures treated with PH-Tau,
43% of activated microglia were also positive for human tau. Cultures treated with tau
had significantly lower proportion of tau containing microglia which correlates to an
insignificant level of Iba1 activation (Figure 6B, graphs). An increased microglial response
could be indicative of conditions that may lead to inflammation, similar to that found in
patients with AD.
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Fig 6. Uptake of tau affects the microglia but not astrocytes in neuronal culture. (A)
Proteins were added to the neuronal culture media and analyzed after 7 days. There is
no significant change in the amount of GFAP fluorescence in cultures challenged with
either tau or PH-Tau when compared to control. The addition of the PH-Tau but not tau
appears to activate the microglia which is correlated with the uptake of tau into the cells
(white arrows). Scale Bar: 20 µm. (B) Left: Quantitation of the GFAP levels indicates that
there is no change after addition of tau to cultures. Middle: Iba1 activation indicates that
PH-Tau significantly activates the microglial response. Right: This activation correlates
with the amount of tau uptaken by the microglia in culture. All experiments were performed
three times with 10 images analyzed per experiment. (∗p < 0.05).
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PH-Tau Effectively Mimics AD P-Tau Taken From Human Brain Tissue
Alzheimer’s disease P-tau, soluble, hyperphosphorylated tau extracted from the brains of
human patients was used in similar experiments to those described above. The uptake
of AD P-tau was shown to be similar to tau and PH-Tau and is also blocked by atropine
(Figure 7A top and top graph). Cultures treated with PH-Tau followed a similar pattern of
neurodegeneration compared to the addition of AD P-tau, showing increased βIII-tubulin
at DIV10 followed by a decrease compared to control (Figure 7A bottom and bottom
graph). Furthermore, pre-treatment with atropine resulted in very little loss of βIII-tubulin
compared to control. Finally, in cultures treated with AD P-tau, no change was observed
in GFAP staining, but microglia were activated almost four-fold more than control cells
and almost 80% of these activated microglia were also positive for human tau. Taken
together, these results confirm the validity of PH-Tau as a good mimic for AD P-tau and
can be used as a surrogate in future studies.
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Fig. 7 AD P-tau addition to neuronal cultures has similar effects as PH-Tau. (A) AD
P-tau is uptaken after incubation of 24 h and atropine blocks this uptake. The white arrow
indicates where tau (green) is localized near the nucleus. No tau is observed in neurons
pre-treated with atropine. Quantitation of uptake is observed in the top graph on the right.
At DIV10, β-III tubulin appears to increase compared to control followed by a sharp
decrease over time, see DIV12 and DIV14. The pre-treatment with atropine blocks the
decrease in β-III tubulin levels. These changes are observed by confocal microscopy
(images) and by quantitation of tau uptake (bar graph, top right) or β-III tubulin
fluorescence (bar graph, bottom right). (B) Activation of microglia is observed upon
addition of AD P-tau and this activation is correlated with the uptake of protein (indicated
by the white arrows). GFAP levels are observed in the top row and activation of microglia
is observed by an increase in fluorescence of Iba1. Bar graphs show levels of GFAP
fluorescence (left), quantiation of Iba1 activation (middle) and AD P-tau uptake (right)
Scale bar: 20 µm. All experiments were performed three times with 10 images analyzed
per experiment. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
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Histological Evaluation of Neurodegeneration in CA3 Region of the Hippocampus

Mice received a stereotaxic intracranial injection of pure artificial cerebral spinal fluid
(aCSF) or either tau or PH-Tau dissolved in aCSF. Forty-five days post injection, mice
were perfused with 4% paraformaldehyde and brains were dissected and post fixed for 2
h. Coronal cryosections were stained with Haemotoxylin and Eosin (H&E). These images
are representative of the (A) aCSF-injected, (B) tau-injected, and (C) PH-Tau-injected
mice (Figure 8). The arrow indicates the injection site, and the box represents the imaged
area shown on the right panels. The aCSF and wild-type tau injected mice show relatively
healthy neurons as demonstrated by the light appearance of neurons and their
morphological integrity. Whereas the PH-Tau injected mice show relatively unhealthy
neurons as evident from nuclear condensation based on intense staining and the irregular
shape of the cell body.
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Fig 8. Neurodegeneration observed in the CA3 region of the hippocampus.
Stereotaxic intracranial injections were performed using (A) aCSF, (B) tau, and (C) PHTau. After 45 days, the brains were harvested and prepared by cryosectioning after
fixation. The arrow indicates the injection site and the box represent the imaged area
shown on the right panel. H&E staining was performed to follow changes in neurons in
the CA3 region. Healthy neurons were observed in the aCSF and wild-type tau injections
whereas condensed nuclei and changes in cellular morphology was observed when PHTau was injected.
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Discussion

In this study, I have observed that recombinant tau and pathological tau can be taken up
from the culture media into cell lines, microglia, and neurons and that this uptake activity
involves muscarinic receptors. The addition of normal tau to neurons promotes neuritic
extension, while PH-Tau leads to the disruption of neuritic processes and accumulation
in the somatodendritic compartment. These findings suggest a novel mechanism for the
pathogenesis of hyperphosphorylated tau and demonstrate additional functions for
normal tau. I have further confirmed previous study, done by our lab which showed that
PHTau mimics AD P-Tau in cultured neurons. Both forms of tau caused the disruption of
neuritic processes and accumulation of tau aggregates in the somatodendritic
compartment. The addition of tau to cell and neuronal cultures has been previously
studied (Frost et al., 2009; Nonaka et al., 2010; Guo and Lee, 2011; Wu et al., 2013;
Sanders et al., 2014; Wu et al., 2016; Evans et al., 2018). Research has indicated that
the minimal unit for uptake is trimeric tau (Mirbaha et al., 2015). These tau trimers also
appear to be the minimal tau toxic unit in both AD and PSP (Shafiei et al., 2017). Native
gel electrophoresis indicates that the tau and PH-Tau that I was using are both mixtures
of oligomeric states but that PH-Tau appears to be composed of a greater number of
higher order complexes (Figure 9). Furthermore, when seeded with AD P-tau the number
of higher oligomeric complexes increases indicating the seeding ability of pathological
tau. My experiments show that normal tau is taken up similarly to PH-Tau. However, only
PH-Tau exhibited a toxic effect indicating that it may not be the size of the aggregate that
is toxic, but the phosphorylation state of tau. To determine the importance of muscarinic
receptors in intracellular uptake of tau, I added normal tau or PH-Tau to the culture media
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Fig. 9. Oligomeric stoichiometry of tau changes depending on phosphorylation
state or seeding. (A) Native PAGE analysis of GST-tau and GST-PH-Tau were analyzed
by Native gel electrophoresis on a 10% gel with Native sample buffer (62.5 mM Tris-HCl,
pH 6.8, 25% glycerol, 1% bromophenol blue) without sonication prior to loading, except
for the AD P-tau which was sonicated in a cup sonicator at room temperature for 1 hour
at 50W.The oligomeric stoichiometry appears to be different when comparing the wildtype tau to the pseudophosphorylated form. Furthermore, upon addition of
substoichiometric amounts of AD P-tau or PH-Tau, the GST-tau appears to change its
oligomeric stoichiometry. (B) Changes in oligomeric states by the addition of
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pseudophosphorylation sites were observed when comparing GST-PH-Tau to GST-tau.
These changes are mainly with the loss of monomer and the increase of trimer. (C) GSTtau was seeded with GST-PH-Tau (left) and AD P-tau (right) at a 25:1 mole ration (GSTtau to seeding protein). The increase in the formation of the trimer was more prevalent in
the AD P-tau seeding than the GST-PH-Tau. (D) Seeding by AD P-tau of GST-PH-Tau
resulted in an even further increase in the presence of the trimer when comparing the
seeding reaction to the GST-PH-Tau alone. (E) The appearance of complex 6 in the
reactions seeded by AD P-tau was faint but highly reproducible. As I have described
above, PH-Tau and AD P-tau addition to neuronal cultures results in similar process
disruption, and suggests that PH-Tau can mimic of AD P-tau. I hypothesize that tau
modifications change its conformation and/or affect its ability to form oligomers. In an
attempt to characterize the changes in tau conformation and/or oligomerization, I
analyzed tau and PH-Tau using native polyacrylamide gel electrophoresis (Fig. 9).
Several different bands could be detected and by comparison to the Native Mark
molecular weight standards (Invitrogen) we could identify a monomeric (band 1), a
dimeric (band 3), or a trimeric (band 5) oligomeric state. Other bands 5 were observed,
one high molecular weight aggregate (band 6) and an intermediate state between
monomeric and dimeric forms (band 2) and one between dimeric and trimeric forms (band
4). Though both tau and PH-Tau had monomers and dimers, clear differences in their
oligomeric stoichiometry could be observed ( Fig. 9B). The levels of monomer in the PHTau were decreased 0.5-fold when compared to tau (p=0.018). Conversely, there was an
increase of 1.9-fold in the trimer conformation of PH-Tau. Observed experimental
changes in the oligomeric stoichiometry may be indicative of nucleation of aggregation,
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in vivo, by pathological forms of tau. To confirm a “prion-like behavior” of pathological
forms of tau, 1 mole of PH-Tau or AD P-tau was mixed with 25 moles of tau, incubated at
room temperature for 30 minutes, and then analyzed using native polyacrylamide gel
electrophoresis (Fig. 9A, 9C, and 9E). PH-Tau caused a 1.3-fold increase in the trimeric
conformation. More strikingly, the addition of AD P-tau to the tau protein resulted in
significant increases in the trimeric conformation (2.5-fold, p=0.051) and the intermediate
conformation band 4 (1.6-fold, p=0.011). With this mixture, the pattern resembles more
the pattern of PH-Tau than that of tau (compare lanes 1, 2 and 4, Fig. 9A, and graphs
Fig. 9B and C). The appearance of the high molecular weight aggregate (band 6), absent
from the normal tau cannot be statistically quantitated as the intensity of the band is low,
but its appearance is reproducible over multiple experimental trials ( Fig. 9E). This change
in oligomeric stoichiometry of tau, which is nucleated by AD P-tau, confirms the prion-like
activity of AD P-tau consistent with our previously published results (Alonso, GrundkeIqbal et al. 1996). Comparison of PH-Tau and the pronounced effect of AD P-tau
nucleation of tau oligomerization compared to PH-Tau, which added in similar
stoichiometry, indicated PH-Tau is less potent in transferring its oligomeric state to the
wildtype protein (Fig. 9C, left). Addition of AD P-tau to PH-Tau induced an increase in the
proportion of the trimer conformation (2.0-fold, p=0.0041, Fig. 9D) and the high molecular
weight aggregates (Fig. 9E)

Uptake of tau was only observed in HEK293 cells. Unlike HEK293 cells, CHO cells do not
naturally express muscarinic receptors. Transfection of CHO cells with either M1, M3, or

40 | P a g e

Viktoriya Morozova

Doctoral Dissertation

M1/M3 muscarinic receptors indicated that the presence of these receptors was
necessary for tau uptake (Figure 1C, 3C). To further investigate the role of muscarinic
receptors, cell cultures were pre-treated with atropine, a known muscarinic receptor
antagonist, prior to the addition of tau. Atropine blocked tau uptake in HEK293 cells,
indicating that the presence of muscarinic receptors is correlated with tau uptake. It is
known that cortical neurons, including hippocampal cells have M1 and M3 muscarinic
receptors and so do glial cells (Levey et al., 1994). Neuronal cultures were used to
determine if both forms of tau could be uptaken in the brain. Tau, PH-Tau, and AD P-tau
were all uptaken at similar levels and this uptake was blocked up to 80% by atropine
(Figures 3B,C, 6). The M1 anatagonist pirenzepine blocked uptake in a similar fashion as
atropine, but AF-DX116 and pertussis toxin, were both unable to block uptake. These
results implicate M1 receptors in the uptake of tau (Figure 3C). Interestingly, a
cholinesterase inhibitor is one of the medications prescribed to ameliorate some of the
cognitive deficits of AD (Birks, 2006; Soukup et al., 2017). The present findings that
atropine blocked the PH-Tau uptake could provide an explanation for the limited efficacy
of this therapeutic intervention. Acetylcholine is one of the transmitters in the cortical and
hippocampal circuits, and because PH-Tau transfer to other neurons may be blocked,
other, non-effected neurons, could maintain the synaptic transmission prolonging
persistence of acetylcholine in the synaptic cleft. Complementary to this cholinergic
mechanism was the study of Schmitz et al. (2016), patients with early stages of AD,
clinically silent, have abnormal degeneration of cholinergic neurons. From my
experimental evidence, neurons treated with wildtype tau that were cultured until DIV14
were more organized and had many more aligned neuritic processes compared to the
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untreated neurons (Figure 5). These findings suggest that extra-neuronal tau might be a
physiological signal. Although the presence of tau in the extracellular space is described,
there is no consensus about physiological function for this localization of tau (Chai et al.,
2012; Magnoni et al., 2012; Karch et al., 2013; Bright et al., 2015; Kanmert et al., 2015).
Tau increases the electrical activity of iPSC-derived or primary cortical neurons, in line
with the finding that tau leads to intracellular calcium increase (Gomez-Ramos et al.,
2008; Bright et al., 2015). As such, extracellular tau may play an important
neuromodulatory role for cognition. In agreement with my results, Biundo et al. (2018)
have shown that tau depletion in a mouse model led to age-dependent deficits in memory
and synaptic plasticity, correlating with levels of normal tau expression. Considering the
potential beneficial role of normal tau with respect to the electrophysiological functioning
and morphology of neurons, my study further explored the effects of pathological tau.
Addition of PH-Tau or AD P-tau to the culture medium induced a retraction of the neuritic
processes (Figures 5, 7). This retraction by PH-Tau is noticeable 5 days (DIV12) after
exposure (Figure 5). Similarly, at 45 days post injection of mice injected with PH-Tau, the
neuronal nuclei began to condense and the cell bodies did not appear rounded (Figure
8). Though uptake of wild-type tau and PH-Tau both appear to be mediated via similar
muscarinic receptors, the effects on neurons and microglia are opposite in nature. The
downstream effects of each of these proteins should be further investigated
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Fig. 10 Neuronal culture model system for the development of therapeutic
interventions. I have shown that the neuronal culture system that we use can mimic
neurodegeneration within 2 weeks of preparation. At DIV7, tau proteins are added to the
culture medium for 24 h before exchanging the media to tau free media. Uptake of the
proteins can be observed at DIV8. By DIV10, no tau is observed in the normal tau
cultures, but the levels of βIII-tubulin increase. Cultures treated with pathogenic tau began
to degenerate by DIV10 with significant loss of βIII-tubulin by DIV14. This system can be
used to try out novel therapeutics to either halt degeneration and/or return the neurons to
their original form
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CHAPTER 2

The uptake of tau isoforms

Abstract

Tau is microtubule associated protein that found mainly in the central nervous system
and its primary function is stabilization of microtubules as well as regulation of the axonal
transport. The tauopathies are the disorders that characterised by the accumulation and
aggregation of abnormal tau protein. Some taupathies, for example Alzheimer’s Disease,
progresses gradually in well defined pattern, pointing on the ability of abnormal tau to
propagate through anatomically connected neurons. In previous chapter I showed that
uptake and propagation of pathological tau is could be prevented by blocking muscarinic
receptors. However, in the human brain there are six different tau isoforms which differ
by the presence or abcence of N terminals (0N, 1N or 2N) and the amount of repeats on
microtubule binding domain (3R or 4R). Here I investigated if all tau isoforms can be taken
up by the neurons, simillarly to the longest tau isoform, and if they do, if they follow the
same route of uptake and propagation, through muscarinic receptors. I found that indeed,
all of the tau isoforms can be uptaken by the neurons and this uptake can be blocked by
the atropine. Moreover, I found the uptake of the longest lau isoform was significantly
higer than the other 5 isoforms. Also, the lowest uptake of tau and lowest effect of atropine
was in the isoforms where 2N terminal absent, pointing on involvement of this region on
interactions with the muscarinic receptors. Possibly it could be due to the conformational
change of the 2N tau that allows the interaction with the receptor.
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Introduction

The microtubule associated protein tau is the protein that bind to the tubulin and helps its
assembly into the microtubules with subsequent stabilization of the latter. Tau is the
product of the alternative mRNA splicing of the of the single MAPT gene located on
chromosome 17q21 which consists of 16 exons (Goedert and Jakes, 1990; Hanger et.,
al, 2017). This splicing results in six isoforms that could be found in the adult human
brain. The inclusion of exon 10 results on microtubule binding domain (MBD) comprised
of 4 repeats (4R), while when exon 10 was excluded the MBD of tau molecule has 3
repeats (3R). As a result, 3 of tau isoforms have 3R on MBD and 3 of the isoforms
possess 4R on theirs MBD. The immature human brain expresses only the shortest tau
isoform (0N3R), however during the transition from fetal brain to adult brain composition
of tau isoforms changes from expressing only the shortest isoform to expressing all tau
isoforms. Tau comprised of 4R was shown to have higher microtubule binding ability than
the one with 3R (Goedert and Jakes, 1990). However, the mutations in exon 10 (N279K,
ΔK280, P301L, P301S and S305N) are shown to reduce the ability of tau to bind tubulin
and stabilize microtubules (Poorkaj et al., 1998; Rizzu et al., 1999; Mirra et al., 1999).
Tau isoforms are differed also by the amount of N terminals. The molecule can have no
N terminal (0N), one N terminal (1N) or two N terminals (2N). Based on the amount of N
terminals and amount of the repeats on MBD tau molecule can range from 352 amino
acids to 441 amino acids.

Fibrillar aggregates of tau protein

are the characteristic hallmarks of many

neurodegenerative diseases, named tauopathies, including deseses such as Alzheimer’s
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disease (AD), Parkingson’s disease, progressive supranuclear palsy (PSP), cortical basal
degeneration (CBD), Pick’s disease (PiD) and frontotemporal dementia linked to
chromosome 17 (Braak and Braak, 1991; Hof, et al., 1994; Espinosa, et al., 2008) All of
these tauopaties have very specific clinical and pathological phenotypes, where tau
pathology is found in distinct regions of the brain and involves particular subsets of
neurons and glial cells (Chin, and Goldman, 1996). It was shown before that the tau
pathology in these tauopaties is composed of distinct tau isoforms. (Delacourte, et al.,
1996, 1998; Greenberg, and Davies, 1990; Greenberg, et al., 1992; Sergeant, et al.,
1997, 1999). The imblance in 3R and 4R tau ratios results from the alternative splicing
of MAPT gene and this alternation has been implicated to different tauopaties. Several
mutations in the intron that follows exon 10 were shown to result on increased production
of the transcripts containing exon 10, which in turn results on production of increased
amount of 4R tau and shift in 3R:4R ratio (Spillantini et al.,1998; Poorkaj et al.,1998). For
instance, in FTDP-17, corticobasal degeneration, PSP and many other tauopathies the
3R:4R tau ratios were found highly decreased (Stanford et al., 2000; Stamelou, et al.,
2010; Chambers, et al., 1999). On the other hand, the increased 3R:4R ratios were seen
in Pick’s disease (Chambers, et al., 1999). In AD and, the expression of tau isoforms and
3R:4R ratio is under the debate, however many studies support the notion that the
expression of 4R tau in AD is increased (Connell, et al., 2005; Umeda, et al., 2004;
Yasojima, et al., 1999; Hyman, et al., 2005; Ginsberg, et al., 2006)

The experiments described in the previous chapter were performed using the longest tau
isoform 2N4R. However, all tau isoforms can be found in CNS. The distribution of 3R and
4R tau in healthy adult human brain is approximately 50:50 and as I described above
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both, 3R and 4R tau are involved in tauopathies (Josephs., et al. 2007). Here I asked
the question If all tau isoforms can be uptaken by the cells, similarly to 2N4R tau and if
they do, if the uptake can be blocked by atropine.

Materials and Methods

Methods for cell culture, isolation of primary neuronal cultures, SDS-PAGE and western
blot, immunocytochemistry and confocal microscopy were described in previous chapter.

Purification of tau isoforms. Direct Boiling Method

Different tau isoforms were isolated after being expressed in E. coli. Plasmids containing
cDNAs for various human tau isoforms in pET15b vector were transformed into E. coli
BL21(DE3) chemically competent cells for expression using standard transformation
protocol and tau isoforms were induced as described previously. After induction for 2.5
hours at 37 °C (250 rpm), cells were pelleted by centrifugation at 3200x g for 15 minutes
at 4 °C. The resulting pellet was resuspended in 2 mL of MES and stored at -80 °C
overnight.

Next day resuspended cell pellet was thawed on ice and immediately placed in boiling
water for 20 minutes with manual agitation every few minutes. The obtained cell lysates
were cooled off by on ice for 10 minutes and centrifuged at 13,000g for 20 minutes at 4
°C to remove cell debris and denatured proteins. The resulted supernatants were further
filterered through a 0.22 µ filter and the filtrates containing tau protein were aliquoted and
stored at -80 °C until further use.
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Results

HEK 293 cells can uptake all tau isoforms.

In previous chapter I showed that HEK293 cells and primary cerebellar neurons can
uptake recombinant GST-Tau, GST-PH-Tau (Chapter 1, fig.3). Both of these proteins
representt the longest tau isoform 2N4R,. I asked a question if all tau isoforms have a
similar to 2N4R tau ability to enter the cells or the abcence of N terminals or one repeat
could result in differences in uptake. To answer this question I used recombinant tau
protein and purified all six isoform using dirrect boiling method. The obtained proteins
were verified using SDS-PAGE and Westen blot analysis (Fig. 1B). The proteins were
added to the cell culture medium of HEK 293 cells and incubated for 4 hours. After 4
hours the cells were washed, and procesed for immunocytochemistry. The ICC analysis
demonstrated that all of the tau isoforms can be uptaken by the HEK 293 cells (Fig. 1C)
with the highest uptake being of 2N4R tau folowed by 2N3R tau. I found that the uptake
of the longest tau isoform, 2N4R was significantly higher than any other isoform. The
uptake of 2N3R was significantly lower than full length tau however it was still significantly
higher than the 0N3R, 0N4R and 1N4R. These results point to the conclusion that the
longest tau isoform is more likely be uptaken by the cells and most likely is the one to
propagate from one cell to another.
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Fig. 1 All tau isoforms can be uptaken by the HEK293 cells. Tau isoforms were
purified using the dirrect boiling method and added into the cell media with cultured
HEK293 cells. The cells were incubated for 24hours washed and processed for
immunocytochemistry or western blot. A) scheme of tau isoforms. B) Western blot
analysis of purified isoforms. C) immunocytochemistry of HEK293 cells, showing the
uptake of tau (red), the neuclei counterstained with DAPI (blue) and quantification of the
uptake indicating that all of the isoforns can be uptaken by the HEK293 cells, with the
highest uptake of the 2N4R tau. ICC experiments were performed three times with 10
images analyzed per experiment.Scale bar: 20 µm; (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001)
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The full length tau is more likely to be taken up by the neurons.

In order to verify if neurons will be able to uptake tau isoforms similarly to HEK293 cells I
used primary neuronal cultures isolated from CD1 pups at PN7. Cultures were grown for
7 days and then cell media was spiked with different tau isoforms (400ng/ml). 24hours
post tau addition, cultures were washed with PBS, fixed and prosessed for ICC. I found
that inded all of the isoforms can be picked up by the neurons, however the uptake of the
longest tau isoforms (2N3R and 2N4R) is significantly higher than shorter ones (0N3R,
0N4R, 1N3R and 1N4R) (Fig. 2) I also observed that the uptake of 2N4R tau was slightly
higer than the 2N3R, however the difference was insignificant, Interestingly, the isoforms
that had the highest uptake possesses 2N terminal pointing on the involvement of 2N
terminal

in

tau

uptake.

Fig. 2 The uptake of the longest tau isoforms is significantly higher than other
isoforms, Primary neurons were isolated from CD1 pups at P7 and cultured for 7 days.
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At DIV 7 tau isoforms were added with and without the Atropine. At DIV 8 cultures were
fixed and processed for ICC and double-stained for human tau (green) and β-III
tubulin(red) and viewed under confocal microscope. My results demonstrate that all tau
isoforms can be taken up by the neurons with 2N4R tau being the highest followed by
2N3R tau (A). Immunocytochemistry analysis of the uptake of tau isoforms with and
without atropine by the primary neurons. Atropine can significantly block an uptake of all
tau isoforms, suggesting that muscarinic receptors can mediate uptake of all tau species
(B). The isoforms of tau with 2N inserts are blocked significantly more efficiently with
atropine, indicating that most of tau uptake in those isoforms mediated by the muscarinic
receptors (C). Scale bar: 20 µm. All experiments were performed three times with 10
images analyzed per experiment. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).

Atropine reduces uptake of all tau isoforms in neuronal cultures. In previous chapter
I showed that muscarinic receptors are involved in tau uptake. However, as I mention
above the GST-PH-Tau and GST-Tau are the longest tau isoforms and the regions which
interact with muscarinic receptors could be absent on the shorter isoforms. Here I asked
a question if the uptake all tau isoform can be blocked by the atropine, muscarinic receptor
antagonist. In order Ito answer this question I isolated primary neuronal cultures and
pretreated them with atropine (100 µM) ten minutes prior their treatment

with tau

isoforms. The cultures were incubated for another 24 hours then washed with PBS, fixed
and processed for ICC. I found that pretreatment of the cultures with atropine resulted on
significant reduction in uptake of all tau isoforms pointing that all of the isoforms can
interact with muscarinic receptors and that these reseptors are the main gate of the tau
entrance into the neurons.

Discussion

The progression of most of the tauopaties occurs in stages where the pathology
propagates further through anatomicaly connected brain areas (Braak and Braak, 1991).
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This suggests that abnormal tau protein can be uptaken and release by the neighboring
or interconnected neurons. In the previous chapter I showed that tau can be effortlessly
uptaken by the neurons and this uptake can be prevented by the pretreatment cultures
with M1 and M3 muscarinic receptors antagonists. 6 different isoforms of tau can be
found in the human CNS and all of these isoforms can be involved in the progression of
various tauopaties. The goal of this study was to understand if all of tau isoforms can be
uptaken at the similar rate and by the similar mechanism, involving muscarinic receptors
and if there are differencess in the uptake of the isoforms to understand which region of
tau can be involved in tau interactions with the muscarinic receptors. My results indicate
that indeed, HEK 293 cells and neurons can uptake any of tau isoforms althougth both,
neurons and HEK 293 cells picked up 2N4R tau at the highest rate, The uptake of the
longest isoform was significantly higher than the others 5 isoforms in HEK 293 cells (fig
1C). In neuronal cultures both, 2N4R and 2N3R were taken up with the similar efficiency
which was significantly higher that the other four (Fig. 2A). The difference between 2N4R
tau and 2N3R tau uptake in neurons was insignificant, however my data showed a slightly
higher uptake of 2N4R tau. On the other hand the the differece in uptake of these isoforms
in HEK293 cells was significant. This suggests that the tau isoforms containing 2N insert
are more likely to be transferred between the neurons.

The data suggest that there could be a shift in 3R:4R ratios in tauopaties (Chambers et al.
1999; de Silva et al. 2003; Mott et al. 2005) however to understand the exact levels of
different tau isoforms in the diseased brain is oneorus task as tau accumulates in distinct
pools, soluble and insoluble and quantification of these pools and understanding how they
relate to each other is near to impossible due to posmortem proteolysis and loss of
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neurons which associated with the tauopaties. (Ginsberg et al. 1999; Zhukareva et al.
2002, 2003). The intronic tau mutations which lead to overexpression of 4R tau, the
mutations of the exon 10 that lead to reduced binding of tau to tubulin and the highest
rate of uptake of 2N4R tau that I saw in my experiments could probably partially explain
the presence of mainy 4R tau deposits in FTDP-17. Nevertheless, whether the diseased
brain predominly having 3R tau or 4R tau, both of these forms can be easily taken up by
the neurons. Interestingly, the lowest uptake that I observed was of the isoforms where
2N terminal is not present, pointing that 2N terminal might play a role in the the tau
interactions with the muscarinic receptors especially since atropine also blocked the
entrance of these isoforms with least efficiency (fig.2B). Besides that, this study
demonstrated that the uptake of all of the tau isoforms could be significanly reduced by
the atropine (fig. 2B), pointing that the uptake of all of the isoforms follows the same route
of the uptake. Interestingly, I found that the uptake of isoforms containing 2N insert were
significantly more eficiently blocked by the atropine ( almost 90 percent, figure 2, C)
indicating that the muscarinic receptors is the main gateway of their entrance. The
development of the drugs that will target these receptors could significantly reduce the
propagation of pathological tau and therefore the progression of the disease could be
greatly slowed down.
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CHAPTER 3

The effects of tau and PH-Tau transmission in vivo.

Abstract

Accumulation of the abnormally phosphorylated tau protein is the common mechanism in
dementias collectively called tauopathies. The data provides compelling evidence that tau
is

the

key

molecule

in

neurodegenerative

process

seen

in

AD.

Tau

pseudophosphorylated at Ser 199, Thr 212, Thr 231 and Ser 262 with inclusion of FTDP17 point mutation R406W (PH-Tau) is the tau molecule that can mimic the effect of tau
isolated from AD patients’ brain. In chapter 1 I showed the effect of this protein in vitro,
where it lead to neurodegeneration and microglial activation, and in vivo where it resulted
on morphological changes in cells. The goal of these experiments is to see the effect of
the PH-Tau on the memory of the healthy, non-transgenic mice when unilaterally injected
in minute amounts into the mice hippocampus. My data showed that in six-month post
injections mice who received PH-Tau were experiencing cognitive decline and significant
increase of activated microglial activation compared to mice who received tau or vehicle
injections. These results indicate that even minute amounts of this toxic protein can have
detrimental effect on the brain leading to neuroinflammation and cognitive decline.
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Introduction

Tau is microtubule associated protein and the main biological activity of tau protein is to
bind the tubulin and promote its assembly into microtubules and to stabilize the
microtubules. The experimental evidence suggests that the spread of tau pathology in
vivo involves the propagation of abnormal tau species along neuroanatomically
connected brain areas. This propagation could occur through a “prion-like” mechanism
which involves transfer of abnormal tau seeds from one neuron to another and
recruitment of normal tau in the latter to generate new tau seeds (Mudher et al, 2017). De
Calignon et al. 2015, demonstrated spread of tau pathology in a mouse model in which
expression of human tau was restricted to the entorhinal cortex only. This suggests that
seeds that were generated in the entorhinal cortex propagated to brain regions connected
to the entorhinal cortex. Other studies also showed the spread of pathology and cognitive
decline in mice due to expression of pathological tau in tau transgenic mice (Clavaguera
et al., 2009; Stancu et al.,2015). Di et al, 2016 showed the effect of conditional expression
of pathological tau in a transgenic mouse model that was generated by our lab. These
animals express Pathological Human tau (PH-Tau) which is the longest isoform of tau
pseudophosphorylated at Ser 199, Thr 212, Thr 231 and Ser 262 with inclusion of FTDP17 point mutation R406W. Pseudophosphorylation is used to mimic the phosphorylation
at the sites named above by substitution with glutamic acid for Ser or Thr. These mice
have the potential to express PH-Tau before birth, and even though the level of
expression is higher in hippocampus, PH-Tau can be found throughout the brain. In these
animals, pathological tau induces cognitive decline, synaptic dysfunction and neuronal
loss. Previously our lab had shown that PH-Tau is sufficient to induce microtubule
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disruption and membrane blebbing in cells (Alonso et al., 2010) and cognitive decline and
changes in mushroom bodies in Drosophila (Beharry et. al., 2013) In these systems, it
appears that PH-Tau can interact with normal tau, pulling it into aggregates and causing
it to take on toxic characteristics in a prion-like manner. All these studies were done with
the system where PH-Tau was expressed by the organism and proved that this
expression of PH-Tau leads to devastating changes in the organism.

My study, described in previous chapter demonstrated that not just constant expression
of PH-Tau but also stereotaxic intracranial injections of a minute amount of GST-PH-TAU
into the hippocampus of CD1 mice resulted on morphological changes in cells when the
brains were viewed 45 days post injections. The same study showed that there were no
changes in cellular morphology in the brain of mice who received GST-tau or vehicle
injections, pointing that the observed morphological changes were developed by the
presence of PH-Tau. I hypothesized that PH-Tau is a form of tau that is particularly
susceptible to spreading to neighboring neurons and this spread of PH-Tau might lead to
inflammation, neurodegeneration and memory loss. To test this, I injected recombinant
GST-tau and GST-PH-Tau monomers into the dentate gyros of the hippocampus of
healthy CD1 mice. The main goal of this study was to understand if the injections of PHTau will result on memory deficit seen in the animals that express PH-Tau continuously.
Another goal of this study was to characterize the effects of these injections using Iba1
(activated microglia), GFAP (astrocytes), tau PThr231, PHF1. Here I will show that the
injections of minute amounts of PH-Tau resulted on memory deficit, and microglial
activation within six-month post injection.
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Materials and Methods

The methods for stereotaxic injections, immunohistochemistry, and confocal imaging
described in chapter 1.

Novel Object recognition test

6-month-old CD1 mice were housed separately 3 days prior to testing and were housed
separately until it was sacrificed. Two tests were conducted, 1st test prior the stereotaxic
intracranial injections and 2nd test 6 months after the injections. Each test was conducted
in 3 consecutive days.

Day 1: mice was placed into the testing room for 1 hour to accommodate it to the testing
room. 1 hour later, mice were place into the testing arena (1 mouse at the time) where it
was left alone for 5 minutes to habituate to the arena and then safely placed back into the
home cage. The arena was cleaned with water and 70% ethanol between each mouse.

Day 2: mice was placed into the testing room for 1 hour to accommodate it to the testing
room. 1 hour later, mice were place into the testing arena (1 mouse at the time) where it
was left alone for 5 minutes to habituate to the arena and then safely placed back into the
home cage. Then 2 identical objects were placed into the arena and mice was returned
into the arena. Mice were left in the arena for 5 min to familiarize itself with the objects.
At the end of 5 minutes mice were placed into the home cage until next day.

Day 3: mice was placed into the testing room for 1 hour to accommodate it to the testing
room. 1 hour later, mice were place into the testing arena (1 mouse at the time) where it
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was left alone for 5 minutes to habituate to the arena and then safely placed back into the
home cage. Then 2 identical objects were placed into the arena and mice was returned
into the arena. Mice were left in the arena for 5 min to familiarize itself with the objects.
At the end of 5 minutes mice were placed into the home cage. 6 hours later mice (one by
one) were placed into the arena with 2 different objects, 1 old (familiar) and 1 new (novel)
and left to explore the objects for 3 min under the recording. After the 3 min each mouse
was returned to the home cage. Later the videos were analyzed, and time mice spent
exploring each object was recorded.

Stereotaxic injection

The stereotaxic injections were done as described in Chapter 1 at the following
coordinates set from bregma: AP: + 2.00mm, ML: + 2.mm, DV: −2.00 mm. The mice were
injected with 2 µL of 2 µg/mL of either PBS, GST-tau, or GST-PH-Tau with the use of a
Hamilton syringe at a rate of 0.5 µL/min for 4 min of total injection time with a KD Scientific
Syringe Infusion Pump.

Brain Processing

Mice were anesthetized with 0.3 mL urethane (1 g/mL) and transcardially perfused with
0.1 M phosphate buffered saline (PBS). Then brains were isolated, and two hemispheres
were separated. The injected hemisphere was processed for IHC as described in Chapter
1 and the second hemisphere processed for western blot.
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Results

GST-PH-Tau injections lead to low performance on Novel Object Recognition test.
Previously we saw that stereotaxic intracranial injection of GST-PH-Tau into mice
hippocampus led to morphological changes in the cells when viewed after 45 days after
the injections, as described in Chapter 1. The mice who received injections with GST-Tau
or vehicle showed no changes in cellular morphology, indicating that the morphological
changes in cells seen in GST-PH-Tau injected mice are due to GST-PH-Tau and not due
to the injection itself. This time we wanted to see if the injections of these proteins will
result in changes on memory test performance. To test this, first we selected 6 months
old CD1 mice and tested their memory using the Novel Object Recognition (NOR) test.
Only mice who performed good (approximately 85% of all tested mice) on this test were
used for the future studying. After the initial NOR test mice were randomly divided into 3
groups and anesthetized and injected with 2µl of GST-PH-Tau (2µg/ml, total amount
400ng), 2µl of GST-Tau (2µg/ml, total amount 400ng) or 2µl of PBS. Mice were returned
back to the animal facility and their performance was analyzed. My results indicate that
mice who received GST-PH-Tau injections had significantly lower performance on NOR
test compared to their initial performance and to their littermates who received GST-Tau
or vehicle injections. There were no significant differences between initial and final NOR
performances in groups that received GST-TAU and vehicle also there was no significant
differences between those two groups. (Fig 1 A and B) These results indicate that GST-
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PH-Tau is responsible for memory loss and therefore underperformance on NOR test.

Fig. 1 GST-PH-Tau Injections leads to loss of memory in CD1 mice. CD1 mice was
tested on Novel Object Recognition Test (NOR) prior to and 6 months after GST-Tau
(400ng), GST-PH-Tau(400ng) or PBS hippocampal injections. My results indicate that all
mice received GST-Tau injections were performing on test significantly worse comparing
to their performance prior the injection and comparing to the mice who received PBS or
GST-Tau injections. There were no significant differences observed in Control mice or
mice injected with GST-Tau. Mice: control (n4); GST-tau (n4); GST-PH-Tau (n6) (∗p <
0.05)
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The injections of GST-PH-Tau result on microglial activation and increase in PHF1
positive neurons in CD1 mice. Based on the results I obtained during the behavior
studies it was obvious that mice injected with GST-PH-Tau undergo memory decline. To
understand what underlines these dramatic changes I sacrificed the mice, removed the
brains and processed for immunohistochemistry. The half-life of tau protein is
approximately 23 days (Yamada et. al., 2015) which rules out the possibility of the
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injected tau to be detected six months after the injection. However, the outcomes of

Fig. 2 Stereotaxic GST-PH-Tau injections results in microglial activation and
significant increase in PH1 positive cells in CD1 mice. CD1 mice received stereotaxic
injections of PBS (control), GST-Tau or GST-PH-Tau at 3 at P90, 6 months later mice
were sacrificed, and the brain were processed for IHC and probed for IBA1 (activated
microglia) and PHF1 (pared helical filaments) hippocampi and cortices were observed
under confocal microscope and relative fluorescence quantified using image j software.
(A). The results demonstrate significant higher activation of microglia in group received
GST-PH-Tau as compared to Control group or GST-Tau. The phosphorylation at Ser
396/Ser 404 also was significantly higher in GST-PH-Tau group compared to control (B).
Scale bar: 75 µm. Mice: control (n4); GST-tau (n4); GST-PH-Tau (n6) with 20-25 images
analyzed per group. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
these injections could be determined by looking at markers such as phosphorylation and
inflammation. The neurodegeneration is usually accompanied by the inflammation and
the increased amount of activated microglia is a good marker to identify these
inflammatory processes. And indeed, the immune-histological staining showed significant
increase in activated microglia in the brain of the mice who received GST-PH-Tau
injections compared to control mice and mice who received GST-Tau injection.
Phosphorylation at the certain tau residues is another marker that could be related to
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neurodegeneration. The PHF1 antibody recognizes tau phosphorylated at Ser
396/Ser404 which are two sites found phosphorylated in tau in paired helical filaments.

The immunohistochemical analysis showed a significant increase in PHF1 positive cells
in the brain of GST-PH-Tau injected mice compared to the mice received vehicle
injections. I also observed some increase in phospho-tau at ser 396/ser404 in mice
injected with GST-tau compared to control, however this increase was insignificant.
Taken together these results indicate the increase in tau phosphorylation and the
inflammatory processes in the brain of the mice who received the GST-PH-Tau.

Discussion

In the Chapter 1, I had shown that PH-Tau is the pathological tau protein with the
properties similar to AD-P tau. In previous studies done by our lab we saw the effect of
the continuous expression of this protein on memory in vivo using mouse model (Di et al,
2016) and drosophila (Behary et al 2014). In both models the expression of PH-Tau led
to cognitive decline. In the same Chapter I also described the effect of GST-PH-Tau
stereotaxic injections on the cell morphology observed 45 days post injection. Here I
wanted to see if the GST-PH-Tau injected into the hippocampal area will result on memory
deficit, similar to that that seen in the animals who expresses PH-Tau continuously.
Normally, when mice face new object, they are tenting to explore it and will spent more
time near the novel object (Antunes and Biala, 2012). However, if mouse has a memory
deficit, after the short period of time it cannot remember the object, it was introduced to
previously, and will not spent the majority of the time near the novel object. The Novel
object recognition test is designed to test cognitive and memory deficits in rodents and it
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is being used frequently to assess the memory declines in transgenic animals with CNS
impairments (Clarke et al. 2010; Taglialatela et al. 2009). In my experiment each mouse
was tested twice with NOR task. The first test was administered prior the stereotaxic
injection and the second test was administered 6-month post injection. The Discrimination
index calculated based on this task performance is the score ranging from negative one
to positive one and it reflects mice success or failure to recognize novel object (Aggleton
et al. 2010; Aubele et al. 2008; Burke et al. 2010; Oliveira et al. 2010; Silvers et al. 2007).
Mice with intact memory should have positive score close to 1. And indeed, the first NOR
showed that all mice had very high discrimination index (fig 1, left). However, when the
task was administered the second time, the discrimination index in the group of mice who
received injections with GST-PH-Tau fall significantly, while the discrimination indexes of
control group and group received GST-tau injections was only slightly below than their
initial performance. This slight decrease in NOR performance I observed in control or
GST-tau group could be contributed to the age of the mice. However, the significantly
lower performance of the GST-PH-Tau mice cannot be explained by the aging alone. The
only suitable explanation of this memory decline is that the injections of GST-PH-Tau
resulted in changes in the brain, which in turn resulted in cognitive decline. The
neurodegeneration is very often accompanied by the neuroinflamation (Bellucci et al.,
2004; Ikeda et al., 2005; Yoshiyama et al., 2007; Sasaki et al., 2008; Zilka et al., 2009)
One of the signs o neuroinflammation is the activation of microglial cells. Microglia are
the phagocytic cells that act like microphages in the CNS and their excessive activation
can exacerbate tau pathology (Bhaskar et al, 2010). The activated microglia can secrete
cytokines, which can promote hyperphosphorylation of tau (Heneka, et al., 2013; Liu, et
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al., 2014). Activated microglia can also secrete tau in the exosomes, thus further
promoting

tau

propagation

(Asai

et

al.,2015;

Clayton

et

al.,

2017).

The

immunohistochemical analysis of the mice brain showed that indeed, the mice who
received GST-PH-Tau injections had significantly higher levels of activated microglia,
when compared to control mice or mice who received GST-tau injections, pointing on
neuroinflammation processes in the brain. I also observed significantly higher levels of
phosphorylation at Ser 396-404 in GST-PH-Tau injected mice when compared to control
mice further pointing on harmful effect of GST-PH-Tau.

To conclude, the memory decline, observed in mice who received PH-Tau injection
couldn’t be contributed by the age of the mice or the injections itself as the rest of the
mice had no significant change in NOR performance, nor in levels of IBA1 positive cells.
I believe that these are the results of GST-PH-Tau interactions with the endogenous tau,
which promoted microglial activation which in turn could affect the phosphorylation of tau.
Nevertheless, this experiment shows the toxicity of GST-PH-Tau, and it’s devastating
effect on the memory and cellular changes when injected even in minute amounts into
the brain of the healthy mice.
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CHAPTER 4

The effects of Direct Current Stimulation on PH-Tau accumulation in vivo and in
vitro.

Abstract

Pathological human tau protein (PH-Tau) mimics the effects of tau isolated from
Alzheimer’s disease patients. I showed above that when PH-Tau is added to a cell media
of cultured neurons it can be taken up by these neurons, resulting on accumulation of the
proteins in somatodendritic compartment as well as disruption of microtubules and
neurodegeneration (Chapter 1). It was shown that Direct Current Stimulation (DCs)
influences stem cell migration, proliferation and differentiation (Samaddar et al., 2016).
Besides that, it was demonstrated that DCs promotes the upregulation of heat shock
proteins (Mekhael et al., 2019) which are responsible for targeting and degradation of
misfolded proteins. Meanwhile, the experiments done to understand the effect of DCs on
cellular level are very scares, there are even less studies to seek and explore whether
DCs can reduce or slowdown neurodegenerative processes like those seen in
Alzheimer’s Disease. This study was designed to understand the effects of DCs in vitro
and in vivo. For my in vitro studies I studied the effect of DCs on healthy neurons and
neurons that undergo neurodegeneration. I hypothesized that increase in Heat shock
proteins will result in the enhancement of misfolded protein degradation which might
slowdown neurodegeneration in neuronal cultures exposed to PH-Tau. The addition of
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PH-Tau to the primary neuronal cultures was used to determine if DCs will lead to the
reduction of cytoplasmic PH-Tau and slow down the neurodegenerative processes
initiated by the protein. For my in vivo studies I studied the effect of transcranial DCs
(tcDCs) using transgenic mice model with conditional PH-Tau expression. My results
demonstrated that indeed, DC stimulation resulted in the upregulation of HSP 70 and lead
to a decrease in PH-Tau accumulation in vivo and in vitro through activation of
degradation pathway.

Introduction

Transcranial Direct Current stimulation (tcDCs) was shown to increase cognitive functions
in healthy individuals (reviewed by Indahlastari et al., 2021) However, the effect of Direct
Current (DC) stimulation on improving of memory in the individuals suffering with mild
forms of dementia is controversial and needs further investigation. Some studies suggest
that tcDCS, especially when done for prolonged periods of time leads to improvement of
cognitive functions in individuals diagnosed with AD (Boggio et. al., 2011, Bystad et. al.,
2017). Although, other studies show that there is no significant improvement in cognitive
abilities between AD patients that underwent tcDCS compared to sham group (Bystad et.
al., 2016). In addition, (Mekhael et al., 2019) in their in vivo studies showed that one
session of trans-spinal DC Stimulation leads to significant increase in Hsp70, a vital
protein involved in mechanisms responsible for the identification, sorting and degradation
pathological and misfolded proteins. Based on these findings we asked if tcDCS will also
result in upregulation of these chaperones and if this increase in HSP 70 will lead to
enhanced clearance of pathological proteins, such as pathological, hyperphosphorylated
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tau and reduce or slow down neurodegenerative processes similar to that seen in
Alzheimer Disease (AD).

Heat shock proteins 70 (Hsp70) are very conserved molecular chaperones that are
expressed in most of the compartments of all eukaryotic cells. These are the chaperones
that normally assist with proper protein folding and scan the proteome for aggregated and
misfolded proteins and initiate their turnover by linking them to the degradation pathways
(Mayer, 2013). This chaperone family plays important roles in cellular stress responses
and protein quality control (PQC). In the framework of PQC, it cooperates with the
ubiquitin-proteasome system (UPS) to clear damaged and dysfunctional proteins in the
cell (Maiti, et al., 2016, Morozov, et al.,2017) Some of these chaperones expressed
constitutively and some of them induced during the stress. The proper levels Hsp70 is
critical to normal protein homeostasis, however during the advanced stages of diseases
associated with abnormal accumulation of proteins, such as tauopathies, the expression
of these chaperones appears to be normal or even reduced (Umeshl et.al.,2012).
Paterson and his group, showed that Hsp70 plays protective role in tau induced
neurodegenerative processes by inhibiting tau aggregation by preventing the formation
of tau fibrils and oligomeric intermediates suggesting that upregulation of Hsp70 proteins
could be a potential strategy for treatment the tauopathies (Patterson, et.al., 2011)

Tau is one of the major microtubule-associated proteins (MAP) and it can be found in the
axons of the neurons of the central nervous system (CNS) (Binder, et. al., 1985). The
biological function of tau is to bind to tubulin and promote its assembly and stabilization
into microtubules (Weingarten et al., 1975). When tau becomes hyperphosphorylated, the
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conformation is changed, it loses the ability to bind tubulin, and this disrupts the preformed microtubules. In Alzheimer’s disease (AD) patient’s hyperphosphorylated tau (AD
P-tau) polymerizes into paired helical and straight filaments which form neurofibrillary
tangles inside the neuron, resulting in neurodegeneration and ultimately the death of
neurons (Alonso et al., 1996). It has been shown that hyperphosphorylation of tau at
Ser199, Thr212, Thr231 and Ser262 with inclusion of the FTDP-17 R406W mutation
(Pathological Human Tau, PH-Tau) is sufficient to induce a pathological conformational
change in tau, a structural change similar to that found in AD P- tau (Alonso et al., 2010).
Pathological human tau (PH-Tau) is a pseudo-phosphorylated form of tau which mimics
the effects of tau isolated from Alzheimer’s disease patients. Recently we found that when
PH-Tau added to a cell media of cultured neurons can be taken up by these neurons.
This uptake results in the accumulation of PH-Tau in the somato-dendritic compartment
of the cells as well as the disruption of microtubules and neurodegeneration, as shown in
Chapter 1.

In this study I used recombinant pathological human tau (PH-Tau) and double transgenic
mice expressing PH-Tau. PH-Tau is the longest tau isoform pseudophosphorylated at
Ser 199, Thr 212, Thr 231 and Ser 262 with inclusion of FTDP-17 point mutation R406W.
Pseudophosphorylation was achieved by substitution with glutamic acid for Ser or Thr
and is used to mimic the phosphorylation at the sites named above.

Experiments presented here were designed to demonstrate the effects of the DC
stimulation on PH-Tau accumulation in vitro and in vivo. tcDCS results in upregulation of
Hsp70 proteins in the brain of healthy mice and mice expressing high levels of PH-Tau.
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Also, tcDCS lead to reduction in PH-Tau levels in our PH-Tau expressing mice. In order
to better understand the mechanism behind tcDCS-induced PH-Tau reduction I used
healthy neural cultures and PH-Tau treated cultures that undergo neurodegeneration due
to PH-Tau uptake. My in vitro results were consistent with results obtained in my in vivo
studies and showed an increase in Hsp70 in stimulated cultures. The stimulated cultures
exposed to PH-Tau had significantly reduced accumulation of PH-Tau compared to
unstimulated cultures. Lastly, I will also show that this tcDCS induced-reduction in
accumulation of PH-Tau degradation pathway.

Materials and Methods

The methods for isolation of primary neuronal cultures, protein induction and purification,
immunocytochemistry and confocal microscopy described in chapter 1.

Antibodies

The primary antibodies used in this work are as follows: tau-13 (mouse, 1:1,000,000 for
Western blot, 1:1000 for immunohistochemistry), βactin (1:2500, Santa Cruz,
Cat#SC4778), β-III tubulin (chicken, 1:1000, Abcam, Cat#AB107216), Hsp70 (mouse,
1:1,000 dilution Santa Cruz Biotechnology (3A3) sc-32239 Lot#(L2018)) GAPDH(rabbit,
1:1,000, Invitrogen)DC stimulation of neuronal cultures

Neurons (DIV 7) were DC stimulated, 1 time, 2 times or 3 times. Stimulations were done
for 90 min at 55.5 V/m first session and 37 V/m second and third sessions. Stimulations
were given 48 hours apart. The pattern of stimulation is indicated in each case.
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Preparation for repeated Transcranial direct current stimulation (tcDCs)

Using stereotaxic techniques, a canula was secured to the middle of the skull to allow for
multiple stimulation sessions. Animals were weighted and anesthetized through
intraperitoneal injections of ketamine/xylazine (100:10 mg/kg). With animals affixed to the
stereotaxic stage, the skull was exposed through a midsagittal incision and underlying
tissue removed. A plastic canula was secured to skull using biodegradable glue. Using a
scalpel point, 1mm wide transparency (depression made in the skull) was made near
perimeter of canula. A stabilizing screw was placed no more than 1mm deep from surface
of skull. Then cold cure (liquid) mixed with (methyl powder) to produce dental resin that
was used to further secure canula. The mouse was placed on warming pad until animal
recovered from anesthetic.

Transcranial direct current stimulation (tcDCs)

Following canula application procedure, mice recovered for 48h and then were stimulated
six times with 48-hour intervals in between each stimulation, at 0.1mA current for 40
minutes each. To stimulate mice, canula was first filled with 0.9% NaCl saline solution
and the electrode was attached to canula through a male luer lock at end of electrode.
The reference electrode was placed on mouse’s tail using ¾ inch flat cotton wick
saturated in saline solution.
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Immunofluorescent Staining

Animals were euthanized through intraperitoneal injection of a lethal dose of ketaminexylazine (100:10 mg/kg) solution 48 hours after last stimulation. Tissue was fixed through
perfusion with 0.1M PBS and 4%PFA. The brain was then removed and processed for
immunofluorescent staining as described in Chapter 1.

Preparation of brain lysates for SDS-PAGE and Western Blot

After the last stimulation, mice were anesthetized through intraperitoneal injections of
ketamine/xylazine (100:10 mg/kg). Brains removed from animals’ skulls were first put in
sterile Petri dishes placed on wet ice. Right sensorimotor cortices were then dissected,
weighted, and frozen on dry ice within 5 minutes following the sacrifice of animals. Next,
using (Abcam Co., USA) protocol, brain cortices were first manually homogenized in a
solution containing the following compounds: 1X protease inhibitor, 1X phosphatase
inhibitor, 5mM EDTA, 1mM PMSF, and RIPA buffer. Furthermore, partially homogenized
samples were sonicated, and centrifuged at 12,000 g for 20 minutes in a centrifuge
apparatus (Beckman, USA) to extract membrane-bound and soluble proteins.
Supernatant proteins concentrations were established using Bradford protein assay (BioRad) inside cuvettes and a Nanodrop 2000/2000c Microvolume Spectrophotometer, with
cuvette capability.

SDS-PAGE and Western Blot described in Chapter 1
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Results

Expression of Hsp70 proteins in control and double transgenic mice

In order to investigate if increase in expression of Hsp70 will help to reduce the
accumulation of pathological tau protein first I wanted to determine what are the relative
levels of Hsp70 in the brain of our double transgenic mice expressing high levels of PHTau compared to control mice. The expression of the PH-Tau in our double transgenic
mice is controlled by the Tet-Off system and regulated by the addition or removal of
doxycycline into the food of these animals (Di. et.al., 2016) The double transgenic mice
that were used in our experiments were off doxycycline since birth and expresses 14% of
PH-Tau. I used double transgenic and control mice hippocampal and cortical
homogenates to perform western blot analysis. The western blot analysis showed that
both groups had similar basal levels of Hsp70 proteins indicating there are no
upregulation in Hsp70 machinery due to the expression PH-Tau (Fig 1, A) in the tautransgenic animals.
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Fig. 1. TcDCS increases HSP70 expression and reduces PH-Tau accumulation in
vivo. Control and DT mice were sacrificed brain removed and processed for western blot
analysis and probed for HSP70 (A). The western blot analysis demonstrated that there
was no significant difference in HSP70 levels between the groups. Double transgenic
mice underwent the surgery and stimulation hubs were installed. Mice were randomly
divided into 2 groups. One group received 6 tcDCs with interval of 48 hours between the
stimulations and then was sacrificed 1 week later. Another group was sacrificed without
stimulations. Brains were removed and 2 hemispheres were separated. One hemisphere
was processed for immunohistochemistry (D)and second for western blot (B) and HSP
70 and tau levels in stimulated vs unstimulated mice were compared (C, E). quantification
of western blot analysis and immuno-histochemical (respectively). Both types of analysis
were consistent with showing significant HSP70 increase in both cortex and hippocampus
of stimulated mice. Both types of analysis also demonstrated a decrease in PH-Tau in
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both cortex and hippocampus. Scale bar: 75 µm. All experiments were performed three
times with 10 images analyzed per experiment. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).

TcDCS upregulates an expression of HSP70 proteins in cortex and hippocampus
of C57 mice.To understand if tcDCS has an effect on the expression of Hsp70 in healthy
brain I installed stimulation hubs on the top of the skull of C57 mice. Mice were left for 4
days to recover from the surgery and then I performed one tcDCs at 0.2mAmp for 40min
and 2.5 hours after the stimulation mice were sacrificed and the brains were processed
for western blot. As a result, I observed 100% and 37% increase in Hsp70 expression in
cortex (fig 2. A) and hippocampus(B) respectively in stimulated mice compared to
unstimulated mice. These results show that tcDCS almost immediately results in increase
in HSP70 expression.

Upregulation of Hsp70 proteins leads to reduction of PH-Tau in cortex and
hippocampus of PH-Tau mice.

To see if the increase in Hsp 70 expression will lead to reduction in accumulation of
pathological tau in our double transgenic mice
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Fig.2
Direct
current
stimulation
upregulates HSP70 expression in mice.
The stimulation hubs were installed onto
C57 mice cranial, and mice were divided
into 2 groups. One group received one 40
min stimulation at 0.2mAmp and then mice
were sacrificed, and brains were processed
for western blot and relative levels of
HSP70 in cortex and hippocampus were
compared. I found a significant increase in
HSP 70 expression in the hippocampus of
stimulated mice (grey bars) compared to
unstimulated mice (black bars, B). The
cortex of stimulated mice also had some
increase in HSP 70 expression; however,
this increase was insignificant (A) (∗p <
0.05)
I randomly divided mice into four groups: stimulated: double transgenic and nontransgenic; unstimulated:

double transgenic and control.

groups were administered six tcDCs at

Mice from the stimulated

0.1mAmp 40minutes each stimulation. The

stimulations were given with 48 hours intervals between each stimulation. One week
following the last stimulation mice were sacrificed, the brains were removed and probed
for human tau and Hsp70 using immuno-histological analysis (Fig.1D, E,) and
biochemical analysis (Fig.1B, D) and compared to unstimulated mice. Western blot
analysis results demonstrated an increase in Hsp70 expression in mice that underwent
stimulations compared to unstimulated mice (Fig.1C) Also, based on immunohistochemical analysis there was significant decrease in human tau, in both cortex and
hippocampus in stimulated mice. (Fig.1E) However based on biochemical analysis the
significant reduction of PH-tau was observed only in hippocampus of stimulated mice.
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Even though the mice were sacrificed a week after the last stimulation I still could observe
an increase in Hsp70 proteins in stimulated mice in cortex (100%) and hippocampus
(40%). After the last stimulation mice also were given novel object recognition test,
however the results of this test did not demonstrate an improvement in mice performance.

DCS leads to reorganization of neuronal cultures

To understand the mechanism of PH-Tau reduction I investigated the effect of DCS in
vitro. I used primary neuronal cultures isolated from CD1 mice on postnatal day 7.
Cultures were grown on glass coverslips for 7 days and then treated with recombinant
GST-PH-Tau (final concentration 400ng/ml). 1 hour after PH-Tau treatment neurons were
stimulated for 90 min, 0.3mA DC, first time. Second and third stimulations were given with
0.2mA current, each stimulation was given 48 hours apart. During the stimulations I
observed movement of the cells and reorganization of the cultures, including movement
of motile cells to one side of the coverslip and accumulation of the cells with long
processes on the opposite side (Fig. 3) I also observed the increase in GFAP positive
glial cells in stimulated cultures.
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Fig. 3. DCs induces immediate change in morphology of the neuronal culture.
Primary neuronal cultures were isolated from PO7 mice and grown for 7 days (DIV7). On
DIV7 cultures were stimulated for 90min at 0.1mAmp. First and the last frame of the video
were taken during 90min DCs of the neuronal culture. The result demonstrates an
increase in length of the processes (blue lines; top graph.) and decrease in size of the
motile cells (bottom graph).
DCS leads to reduction of PH-Tau accumulation in primary neuronal cultures
Following the 3rd stimulation, I saw significant decrease in PH-Tau in stimulated cells
compared to unstimulated cultures (Fig. 4 A (green), and fig. 4 B) Besides that, stimulated
cultures appear to have processes organized into bundles (Fig.4 A (red), and fig. 4 C).
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On the other hand, neurons in unstimulated cultures had significantly less processes and
accumulation of tau in perinuclear region (Fig. 4 A). Moreover, the treatment of neuronal
cultures with PH-Tau 1 hour after the first stimulation showed the same results as I
observed when cultures were treated with tau prior the stimulations, suggesting that these
results are due to upregulation of the degradation pathways rather than due to reduced
uptake. Overall, this data suggests that DC stimulation leads to decrease in PH-Tau
accumulation in primary neuronal cultures and increase in Hsp70 expression.

DCS leads to upregulation of Hsp70 in primary neuronal cultures

To understand if DCS will lead to upregulation of Hsp70 in vitro I used primary neuronal
cultures isolated from CD1 mice at P7. Neuronal cultures were grown for one week and
then separated into the two groups. Stimulated cultures were stimulated 1 time for 90 min
at 0.3mAp and then 2 hours later processed for western blotting and probed with Hsp70
antibodies (Fig. 4 D). As a result, I observed small increase in Hsp70 levels in cultures
that underwent DCS (Fig. 4 E).
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B.

A.

Fig. 4 DS stimulation leads to reduction of PH-tau, increase in HSP 70 and
upregulation of degradation pathway. 7-day old cultures were treated with PH-Tau,
stimulated 3 times for 90 min at with 0.1mAmp current, with 48 hours intervals between
each session. 48hr after last stimulation neurons were fixed, processed for ICC and
double labeled with Tau 13 (human tau, green) and tubulin β-3 (red)(A). B) Stimulated
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cultures have significantly less accumulation of PH-Tau and C) appear to increase in
bundles compared to unstimulated cultures. D) 7 days old neurons were stimulated 1 time
and processed for western blot analysis to determine Hsp70 levels. E) Quantification of
western blot analysis of primary neuronal cultures demonstrated an increase in Hsp70 in
stimulated culture vs unstimulated. 7-day old cultures were treated with PH-Tau and
MG132 and then stimulated 3 times for 90 min with 48 hours intervals between each
session. F.) 48 hours after last stimulation neurons were fixed, processed for ICC and
double labeled with Tau 13 (human tau, green) and tubulin β-3 (red). G.) Quantification
of immunocytochemical analysis indicates that the effects of DC stimulation were blocked
by MG132 pointing that DC stimulation activates degradation pathway. Scale bar: 20µm.
All experiments were performed three times with 10 images analyzed per experiment. (∗p
< 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).

DC stimulation reduces PH-Tau through upregulation of ubiquitin- proteasomal
degradation pathway

To understand if this reduction in PH-Tau accumulation is due to overexpression of Hsp70
and upregulation of degradation mechanisms I used proteasome inhibitor MG--132.
Primary neuronal cultures were isolated from P7, CD1 mice. On day 7 (DIV7) cultures
were treated with PH-Tau (final concentration 400ng/ml) and MG-132 (10 micromoles/ml)
1 hour prior the stimulation and then stimulated 3 times for 90 min with 48hr intervals
between each session. 48hr after last stimulation neurons were fixed, processed for ICC
and double labeled with Tau 13 and tubulin β-3. (Fig. 4 F). The results indicated there
were no significant difference in tau accumulation between stimulated, PH-Tau and MG132 treated cultures and PH-Tau treated unstimulated cultures. (Fig. 4 E) Both groups
had PH-Tau accumulated in perinuclear region of the cell and disrupted neurites. These
results show that the effects of DC stimulation were blocked by MG-132 pointing that DC
stimulation activates ubiquitin- proteasomal degradation pathway
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Transcranial direct current stimulation increases expression of heat shock protein
70 (Hsp70) and slows progression of Alzheimer’s disease (AD) pathogenesis.

Fig 5 demonstrates a schematic representation of the effect of tcDCS on pathological tau
clearance during the disease progression. These data demonstrates that tcDCS leads to
increased expression of Hsp70 which in turn recognizes the pathological, misfolded PHTau and facilitate its degradation by shifting PH-Tau to UPS or through lysosomalautophagic pathway resulting on decreased accumulation of PH-Tau.

Fig. 5 tcDCs increases expression of HSP70 and slows progression of Alzheimer’s
disease pathogenesis. Increased expression of HSP70 is regulated by the heat shock
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factor 1 (HSF1). HSP70 is inducible chaperone protein, that surveys intracellular
environment and works in combination with co-chaperons and co-factors to facilitate the
refolding or degradation of the client proteins to prevent the consequences of tau toxicity.
Several of neurodegenerative or neuroprotective effects of tau toxicity have been
hypothesized through observation of Alzheimer’s disease pathogenesis with its
fundamental basis stemming from tau hyperphosphorylation. The hyperphosphorylation
results on changes in tau conformation and causes it to become unbound from preformed
microtubules leaving microtubule binding domains (MBD) exposed. The substrate binding
sites (SBS) of HSP70 can recognize the hydrophobic polypeptide stretches adjacent to
exposed MBD on abnormally phosphorylated tau. Once abnormal tau is detected it is
shuttled to the proteosome for refolding or degradation through lysosomal-autophagic
pathway or UPS.
Discussion

In this study I have observed that tcDCS leads to upregulation of Hsp70 family proteins
in normal (control) mice, double transgenic mice expressing high levels of PH-Tau and in
primary neuronal cultures. This increase in Hsp70 subsequently resulted in reduction in
PH-Tau accumulation in both, double transgenic mice and primary neuronal cultures
exposed to exogenous GST-PH-Tau. These findings suggest that Hsp70 plays a vital role
for clearance of the toxic PH-Tau deposits and the upregulation of these proteins can be
employed as a potential treatment for tauopathies. The effects of tcDCS on
neurodegenerative disorders including Alzheimer’s disease have been studied by many
groups (Boggio et al., 2006, Ferrucci et al., 2008; Boggio et al.,2009) and shown to be a
quite effective in improving recognition memory in patients diagnosed with mild and
moderate AD (Ferrucci et al., 2008; Boggio et al.,2009; Boggio et al.,2012). There were
also a handful of studies performed to investigate role of Hsp70 family in tauopathies,
including AD showing that Hsp70 directly interacts with abnormal tau leading to its
reduction through favoring its degradation or de-phosphorylation (Dou F et al., 2003;
Petrucelli L et al., 2004; Ambegaokar S. S. and Jackson G. R. 2011; Lackie at al., 2017)
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These studies provided a clear evidence that Hsp70 family plays an important role in
slowing down AD by protective mechanisms in which these chaperones alone or with
their co-chaperones participate. Our studies demonstrated that tcDCS leads to an
increase

in Hsp70 levels as soon as in 2.5h post stimulation and these Hsp70 levels

can stay elevated for at least a week following the stimulations. This effect of tcDCS on
rapid increase and prolong lasting Hsp70 makes it a great candidate as a nonpharmaceutical

intervention that can be used to elevate Hsp70 levels in patients

diagnosed with tauopathies. To investigate the effect of this increase in Hsp 70 levels on
PH-Tau I performed tcDCS in our double transgenic mice expressing high levels of PHTau our results showed an increase in Hsp70 in cortex (100%) and hippocampus (40%)
in stimulated mice, also I saw a decrease in PH-Tau in cortex and hippocampus of these
mice. To better understand the underlying mechanism of this PH-Tau reduction and if it
could be attributed to changes in Hsp 70 levels I designed in vitro experiments where I
conducted DCS on primary neuronal cultures. The results were consistent with the data
obtained in my in vivo experiments and demonstrated that DCS lead to reduced
accumulation of PH-Tau in perinuclear region of the cells.

Hsp70 chaperones bind to misfolded proteins and shuttle them to the lysosomeautophagy pathway or ubiquitin-proteasome system (UPS) for degradation (Mayer,
2013). To understand which pathway is involved in PH-tau reduction I used MG-132, a
potent proteasome inhibitor. I hypothesized that if the increase in Hsp70 due to DCS
upregulates UPS then when I block proteasome function by inhibitors such as MG132 I
should see no decrease in PH-Tau accumulation after DCS. To test this hypothesis, I
treated our primary cultures with MG-132 and PH-Tau one hour prior the stimulation, then
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cultures were stimulated 3 times as described above. The immunocytochemical analysis
demonstrated that indeed, there was no significant difference between the unstimulated
cultures treated with PH-Tau and stimulated cultures treated with MG-132 and PH-Tau.
These results point out that clearance of tau occurs through the UPS pathway.

Overall, my results demonstrate that tcDCS is a good technique to elevate Hsp70 levels
in both, in vivo and in vitro systems. Increased levels of Hsp70 in turn will upregulate UPS
leading to increased clearance of PH-Tau. I believe that this technique will also upregulate
levels of other heat shock proteins, such as Hsp90 and 40. In this study I was looking at
the effects of tcDCS on specifically Hsp70 and I did not examine the effects of other
chaperones. As the follow up study, I will further explore the effects of tcDCS on cellular
level and its utilization as a power tool in managing tauopathies.
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CHAPTER 5

Conclusions

Tauopathies are a class of neurodegenerative disorders characterized by accumulation
of abnormal tau protein. Tau is the microtubule associated protein and its primary
biological function is to bind to tubulin and stabilize microtubules. Tau is intrinsically
disordered protein and undergoes through many posttranslational modifications. The
most studied modification of tau is phosphorylation. Tau has 80 phosphorylation sites so,
20 percent of the tau can be potentially phosphorylated. Previously our lab showed that
phosphorylation of tau at Ser199, Thr212, Thr231 and Ser262 with inclusion of the FTDP17 R406W mutation is the form of tau that mimics the effect of AD-P tau. When tau
hyperphosphorylated at these sites, it cannot bind to tubulin and instead it comes off the
microtubules and accumulates in the cytosol in form of paired helical and straight
filaments. Moreover, this abnormal, hyperphosphorylated tau can bind to normal tau
protein and sequester it from microtubules as well, resulting on disrupted microtubules
and death of neuron. The progression of tauopathies, develops in very ordered manner.
The neurodegeneration starts and progresses throughout interconnected neurons which
points on ability of abnormal tau to travel from one neuron to another. In my studies I
showed this ability of tau to propagate from one cell to another, neighboring cell,
spreading the pathology (Ch1, fig1A, C). I found that PH-Tau can easily get out of the
transfected cell and enter the neighboring cells leading to disruption of the cytoskeleton.
However, I found that this transfer doesn’t occur in all types of cells. I found that CHO
cells when transfected with both types of tau, (PH-Tau and tau) did not display transfer of
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PH-Tau (Ch1, fig1B) unless they co-transfected with M1 and M3 muscarinic receptors
(Ch1, fig1C). The similar phenomena I observed when I added recombinant tau and PHTau into the cell culture media with cultured cells. Both, GST-Tau and GST-PH-Tau were
effortlessly taken up by the HEK cells, however there was no uptake by the CHO cells,
unless they expressed M1 or M3 or both muscarinic receptors. The incubation of primary
neuronal cultures with GST-tau and GST-PH-Tau led to the to the same results I observed
with HEK cells, both types of tau protein were taken up by the neurons The addition of
GST-tau and GST-PH-Tau to the neuronal media also reveal the effects of these proteins
on neuronal wellness. Neurons incubated with GST-Tau for 7 days appeared to have
increased growth of neurites compared to control cultures. On the other hand, neurons
incubated with GST-PH-Tau lost most of the neurites and I found GST-PH-Tau
accumulated in the perinuclear region of the cells. Moreover, I found increased amount
of IBA1 in cultures treated with GST-PH-Tau, which are also were positive for tau 13
(human tau) indicating inflammatory processes in GST-PH-Tau treated primary cultures
and pointing that tau also can be taken up by the microglia. This in turn can exacerbate
the propagation of the PH-Tau by propagating the spread via the exosomes.

Both, neurons and HEK cells express muscarinic receptors, and these receptors were
shown to interact with tau (Gomez-Ramos et al., 2008; Bright et al., 2015) To test my
hypothesis that muscarinic receptors play role in tau uptake, first I used broad muscarinic
receptor inhibitor atropine. The pretreatment of HEK cells and neuronal cultures with
atropine led to no PH-Tau transfer in transfected HEK cells. Also, the pretreatment of the
neuronal cultures with atropine led to 80 percent of GST-Tau and GST-PH-Tau uptake
indicating that indeed, muscarinic receptors are highly involved in tau uptake into the
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cells. After the blocking muscarinic receptors, I still observed some of the uptake of GSTTau or GST-PH-Tau however it was not accompanied by the drastic changes I had
observed in cultures without atropine pretreatment. This uptake took place most likely
due to the alternative routes that were shown by other groups to take place. For example,
Kosik and team showed involvement of low-density lipoprotein (LDL) receptor-related
lipoprotein 1 (LRP1). Theirs’s in vitro studies using H4 neuroglioma cells and iPS-derived
neurons identified LRP1 as the main player in tau endocytosis (Kosik et. al., 2020).
However, these findings could be explained by the high concentration of tau constructs
they were using in their experiments. The group used more than 20-fold higher
concentration of tau when treated the cells (9 µg/ml contrast of 0.4 µg/ml I used in my
study). Another routes of tau transfer between the neurons could be via exosomes (Perez
et al., 2019; Polanco and Götz, 2021), or it could be passively taken up by the cells via
endocytosis, and it could be transferred between the neurons through tunneling
nanotubules (Tardivel, et al., 2016). Moreover, the fact that PH-Tau could be picked up
by the microglial cells also should be taken into the consideration. These routes of tau
uptake/transfer could contribute to 20 percent of tau present in the cells after the
pretreatment with Atropine. My study also demonstrated that PH-Tau developed in our
lab has very similar effect on the neurons as the tau isolated from AD brain, ADP-tau
(Chapter1. fig7.) and the uptake of ADP-tau also prevented by atropine. Atropine is the
broad muscarinic receptor antagonist and will block all the muscarinic receptors. Five
muscarinic receptors were identified, M1-M5. I found that only excitatory muscarinic
receptors are involved with tau uptake/ spread, by using specific muscarinic receptors
inhibitors (Chapter 1 fig3). My results allowed me to eliminate involvement of M2 and M4
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receptors in tau uptake and spread. The deposits of pathological tau can be comprised
of all tau isoforms in AD. And my data showed that all of the isoforms can be taken up by
the HEK 293 cells and neurons. Besides being involved in uptake of tau and PH-Tau
muscarinic receptors are also involved in uptake of all tau isoforms, as the uptake of all
tau isoforms was blocked by the atropine (Chapter 2, fig. 2). Interestingly, not all tau
isoforms are uptaken at the same rates. My data indicated that uptake 2N4R tau is
significantly higher than other isoforms, pointing that this form of tau is prompt to
propagation the most. And indeed, in many tauopathies, including FTDP-17 deposits of
pathological tau comprised predominantly of this isoform (reviewed by Goedert et al.,
2000). Also, while this work showed the necessity of M1 and M3 receptors for the uptake
the role of M5 receptor in all this still not clear and needs to be further investigated.

The stereotaxic injections of tau seeds were previously described by many groups, and
all these groups showed the detrimental effect of pathological tau on the brain of the
animal, (Lasagna-Reeves et al., 2012; Clavaguera et al., 2009; Stancu et al.,2015.;
Kaufman et al., 2016). However, most of these studies were done using the transgenic
animals, which already expressing the pathological tau or were using tau seeds isolated
from the diseased brain. After seeing the effects of the PH-Tau and tau on the neuronal
cultures I also wanted to examine the effect of these proteins in vivo using non-transgenic
CD1 mice. To see the effect of tau/ PH-Tau in vivo I performed the stereotaxic injections
into the hippocampus. First, mice were injected with aCSF of 400ng of GST-Tau and
GST-PH-Tau into the hippocampus and 45 days later and found that GST-PH-Tau
injection led to changes in cell morphology while there were no changes in mice who
received aCSF or GST-Tau. These results raised the question, what the effect of these
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injections on the memory of the mice would be? To answer this question, I performed
behavioral testing on 6-month-old CD1 mice and compared the results of this testing sixmonth post injections. The behavioral analysis showed drastic difference between the
group who received GST-PH-Tau injection and other two groups. The GST-PH-Tau group
had significant decline in ability to identify the novel object during NOR compared to their
ability to do so prior to the injection. The performance of other two groups showed
insignificant decline on NOR when compared to their initial performance. These results
clearly show that the decline in NOR performance is due to GST-PH-Tau (Chapter 3,
fig1). Previously our lab had shown that double transgenic, PH-Tau expressing mice has
memory deficit and this deficit becomes more pronounced with time. (Di., J et. al., 2016).
However, those mice were expressing PH-Tau continuously throughout the lifespan and
the amount of the pathological protein in the brain was consistently high. My results
demonstrated that the PH-Tau seed can lead to the cognitive decline similar to one seen
in the transgenic animals. . The immunohistochemical analysis of these mice also showed
that mice which received GST-PH-Tau injections had significant increase in IBA1 positive
cells (activated microglia) compared to controls and GST-PH-Tau and significant increase
in PHF1 (tau P396-404) when compared to control mice (Chapter 3, fig2). The full effect
of these injections needs to be investigated further however overall, this experiment
shows the drastic, detrimental effect of PH-tau on the memory and the brain of these
animals.

So far, I had shown the effect of tau and PH-Tau in vitro, using the addition of these
proteins into the cultured cells and primary neurons. And in vivo, using the stereotaxic
injections of PH-Tau and tau into the different areas of hippocampus of CD1 mice. In both
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cases I saw detrimental effect of PH-Tau. PH-Tau is the hyperphosphorylated form of tau.
The hyperphosphorylation of this protein at Ser199, Thr212, Thr231, and Ser262 leads

to abnormal amount of the negative charge that changes the protein conformation and
properties. Tau achieves the confirmation that becomes pathological and deliberate to
the normally folded protein and to the host cell. . When we talk about protein misfolding
the heat shock proteins are the one who comes on mind, and specifically HSP70. These
heat-shock proteins expressed in all types of cells and involved with screening,
identification, repair and sorting of misfolded proteins and other molecules. This class of
heat shock proteins were shown to closely interact with tau and play an important role in
tau degradation and repair. I ask the question, what would be the effect of increased
HSP70 expression on PH-Tau? Direct current stimulation is the technique that leads to
increase in HSP70 expression (Chapter 4, fig 2, fig 4D, E). I used DC stimulation to
understand if this approach can stop or at least slow down the neurodegeneration spiked
by the PH-Tau. I found that, DC stimulation can decrease the PH-Tau accumulation in
vitro in neuronal cultures (Chapter 4, fig 4A and B) and in vivo, in double transgenic PHTau expressing mice (Chapter 4 fig1). Moreover, this decrease in PH-Tau expressing
mice most likely due to upregulation of the degradation of PH-Tau, as the experiments
with blocking of degradation pathway using MG132 showed no decrease in PH-Tau after
the DC stimulations (Chapter 4, fig 4F, E). Taken together these results show that DC
Stimulation can be employed as an alternative approach of prevention of PH-Tau
accumulation and as to increase the degradation of already accumulated protein. The
effect of this technique on behavior and the memory needs to be further investigated,
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however it was previously shown that DCS can be used to improve cognitive abilities in
healthy individuals (Kronberg G. et al., 2016; Tatti E., et al., 2016)

To conclude, this work demonstrates that PH-Tau and tau can be taken up by the cells
and spread from one cell to another with involvement of the muscarinic receptors. The
effect of PH-Tau spread is drastic and includes morphological changes in cells,
inflammation, loss of memory and cognitive abilities. Muscarinic receptors inhibitor can
be used as the pharmacological approach to slow down PH-Tau accumulation and
spread. Direct current stimulation can be alternatively applied to decrease the
accumulation of pathological tau by upregulation of degradation pathways.
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